TB drug
Comments
Content
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
Topic Review
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
Çѵ¶Ø»ÃÐʧ¤
ì
1.
à¾×èÍÊÒÁÒöÇÔ¹Ô¨©Ñ
Â
´ÙáÅÃÑ¡ÉÒáÅеԴµÒÁ¼Ùé»èÇÂÇѳâää´é
*
°ÔµÔ¹Ñ¹
ì͹ØÊóìǧÈìªÑ
Â
** ©Ñ¹ªÒÂ
ÊԸԾѹ¸
ìØ2. à¾×èÍÃÙé¨Ñ¡ÂÒÕèãªéÃÑ¡ÉÒÇѳâä
¡Åä¡¡ÒÃÍ͡ĸ
ìÔ¢¹Ò´ÇÔ¸ÕãªéµÅÍ´
¨¹¼Å¢éÒ§à¤Õ§¢Í§ÂÒ
3.
ÊÒÁÒö¹Ó¤ÇÒÁÃÙéÑé§ã¹Í´ÕµáÅлѨ¨ØºÑ¹ÁÒÃǺÃÇÁáÅлÃÐÁÇżÅ
à¾×è͹ӼšÒÃÇÔ¨ÑÂÇÒÃÊÒÃä»ãªé»ÃСͺ¡ÒôÙáÅÃÑ¡ÉÒ¼Ùé»èÇÂÇѳâä
º¤Ñ´Âè
Í
㹻Ѩ¨ØºÑ¹¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâäÕèàËÁÒÐÊÁÕèÊØ
´
ÁÕá¹ÇÒ§àʹÍ
á¹Ð
â´Â¡ÅØèÁ¼ÙéàªÕèÂǪÒã¹»ÃÐàÈÕè¾Ñ²¹ÒáÅé
Ç
àªè
¹
ÊËÃÑ°ÍàÁÃÔ¡Ò
(American Thoracic Society ¾.È. 2537) ¡Ñ
º
ÊËÃÒªÍҳҨѡÃ
(British Thoracic Society ¾.È. 2540) áÅÐͧ¤ì¡ÒùҹҪҵÔä´éá¡è
ͧ¤ì¡ÒÃ͹ÒÁÑÂâÅ¡ (WHO Tuberculosis Unit ¾.È. 2540) áÅÐ
International Union Against Tuberculosis and Lung Disease
(IUATLD ¾.È. 2540) ¡ÅèÒÇä´éÇèÒ¡ÒÃÃÑ¡ÉÒÃÐÂÐÊÑé¹Õèãªé㹻Ѩ¨ØºÑ
¹
à»ç¹ÃкºÂÒÃдѺ¹Ò¹ÒªÒµÔËÃ×ÍÃдѺâÅ¡
ÕèÁÕ»ÃÐÊÔ¸ÔÀÒ¾áÅÐ
»ÃÐÊԸԼŴÕÕèÊØ
´
Õè¨ÐÃÑ¡ÉÒ¼Ùé»èÇÂÇѳâäãËéËÒÂä´éà¡×ͺÃéÍÂÅÐ 100
¶éÒ¼Ùé»èÇÂä´éÃѺÂÒÊÁèÓàÊÁͤú¶éǹ
*
á¾Âì»ÃШӺéÒ¹
ÀÒ¤ÇÔªÒÍÒÂØÃÈÒʵÃ
ì
¤³Ðá¾ÂÈÒʵÃ
ì
¨ØÌÒŧ¡Ã³ìÁËÒÇÔÂÒÅÑ
Â
**ÀÒ¤ÇÔªÒÍÒÂØÃÈÒʵÃ
ì
¤³Ðá¾ÂÈÒʵÃ
ì
¨ØÌÒŧ¡Ã³ìÁËÒÇÔÂÒÅÑ
Â
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
Çѳâäà»ç¹âäµÔ´àª×éÍã¹Á¹ØÉÂìÕ辺ÁÒ¹Ò¹ËÅÒÂ
¾Ñ¹»Õ¨Ò¡¡ÒÃÈÖ¡ÉÒ«Ò¡ÁÑÁÁÕèÍÕÂÔ»µ
쾺ÇèÒÁÑÁÁÕèÁÕ¤ÇÒÁ
¼Ô´»¡µÔ¢Í§¡Ãд١ÊѹËÅѧáÅоºªÔé¹Êèǹ¢Í§´ÕàÍç¹àÍ
(DNA) ¢Í§àª×éÍÇѳâäÍÂÙè㹡Ãд١¹Ñé
¹
áÊ´§ãËéàËç
¹
ÇèÒàª×é͹ÕéÓãËéà¡Ô´âäã¹Á¹ØÉÂìÁÒµÅÍ´
¡èÍãËéà¡Ô´»ÑËÒ
ÊÒ¸ÒóÊØ¢Õè¤Ø¡¤ÒÁ»ÃЪҡÃÑèÇâÅ¡
â´Â੾ÒлÃÐàÈ
¡ÓÅѧ¾Ñ²¹Ò
Çѳâäà¡Ô´¨Ò¡àª×éÍ¡ÅØè
Á
Mycobacterium
tuberculosis ¤é¹¾º¤ÃÑé§ááâ´Â Robert Koch ã¹»Õ
¾Ø¸ÈÑ¡ÃÒª 2425 à»ç¹àª×éÍçáè
§
¢¹Ò´ 0.5 ¶Ö§ 3
äÁ¤Ã͹
äÁèÊÃéҧʻÍÃ
ìäÁèµÔ´ÊÕá¡ÃÁ
äÁè¶Ù¡ÅéÒ§´éÇÂ
¡Ã´ÍÑÅ¡ÍÎÍÅ
ì¨Ö§¶Ù¡àÃÕ¡Çè
Ò
áÍÊÔ´¿ÒÊ (acid-fast
bacilli) Çѳâä»Í´ÁÑ¡¨ÐµÔ´µèÍâ´Â¡ÒÃÊÙ´àÍÒÅÐÍͧ
àÊÁËТͧ¼Ùé»èÇÂÕèäÍ
¨ÒÁ
¾Ù
´
ËÑÇàÃÒÐËÃ×ÍËÒÂã¨Ã´
à¢éÒä»ã¹»Í´â´ÂµÃ§
â´Âàª×éÍÇѳâäÁÕ¢¹Ò´àÅç¡¡Çè
Ò
10 äÁ¤Ã͹
ÊÒÁÒöà¢éÒ件֧Êèǹ»ÅÒÂÊØ´¢Í§Ò§à´Ô
¹
ËÒÂã¨
áÅСèÍãËéà¡Ô´âä
´Ñ§¹Ñ鹨֧ÁÑ¡ÁÕ»ÃÐÇѵÔÊÑÁ¼Ñ
Ê
ã¡ÅéªÔ´¡Ñº¤¹Õèà»ç¹âä
Êèǹ¡ÒõԴµèÍâ´ÂÒ§Í×è¹¹Ñ
º
ÇèÒÁÕâÍ¡ÒʹéÍÂÁÒ¡
ÕèÍÒ¨¾ºä´é¡çâ´Â¡Òô×èÁ¹ÁÇÑÇ´Ôºæ
Õèä´é¨Ò¡ÇÑÇÕèà»ç¹Çѳâä
ËÃ×Íâ´Â¡ÒáÅ×¹àÍÒàª×éÍÕèµÔ
´
ÁҡѺÍÒËÒÃËÃ×ÍÀÒª¹Ð
àª×éͨÐà¢éÒÒ§µèÍÁ͹«ÔÅËÃ×
Í
ÅÓäÊéáÅéÇà¢éÒä»ÍÂÙèã¹µèÍÁ¹éÓàËÅ×ͧ
«Ö觺ҧ¤ÃÑé§ÍÒ¨
ÅØ¡ÅÒÁà¢éÒ¡ÃÐáÊàÅ×Í´ä»Âѧ»Í´
ÊÁͧ
¡ÃдÙ
¡
äµ
ËÃ×ÍÍÇÑÂÇÐÍ×è¹æ
ä´é¶Ö§áÁéÇèÒàª×éÍÇѳâäã¹ÅÐÍͧ½ÍÂ
äÁèà¤Å×è͹äËÇ
¶Ù¡ÓÅÒÂä´é§èÒ´éǤÇÒÁÃé͹
¤ÇÒÁáËé
§
áʧᴴ
ËÃ×Íáʧ-ÍÑŵÃéÒäÇâÍàŵ
ÍÂèÒ§äáçµÒÁ
¤ÇÃ
᡼Ùé»èÇÂÍÂèÒ§¹éÍ 2 ÊÑ»´ÒËìáá¢Í§¡ÒÃÃÑ¡ÉÒ
à¾×è
Í
Å´¡ÒÃá¾Ãèàª×éÍÇѳâää»ÊÙèºØ¤¤Å¢éÒ§à¤Õ§
â´ÂÊèǹãËè
¾ºàª×éÍâä¹Õé㹻ʹ
ÍÂèÒ§äáçµÒÁÍÒ¨¾ºã¹ÍÇÑÂÇÐÍ×è¹æ
ä´é¶Ö§Ë¹Öè§ã¹ÊÒÁ¢Í§¼Ùé»èÇÂÇѳâäà»ç¹âäÕèÃÑ¡ÉÒãËéËÒÂ
¢Ò´ä´éáµè¶éÒäÁèÃÑ¡ÉÒ
¤ÃÖè§Ë¹Ö觢ͧ¼Ùé»èÇÂÍÒ¨àÊÕªÕÇÔ
µ
ä´éÀÒÂã¹ 5 »Õ1
â´ÂʶԵÔÕèÃǺÃÇÁâ´Âͧ¤ì¡ÒÃ͹ÒÁÑÂâÅ¡2
µÑé§áµè
»Õ¾.È. 2534 áÅкǹãËÁèàÁ×è
Í
¾.È. 2541
¾ºÇè
Ò
»ÃЪҡÃâÅ¡¶Ö§Ë¹Öè§ã¹ÊÒÁ
ËÃ×Í»ÃÐÁÒ³ 1,900
ÅéÒ¹¤¹3 µÔ´àª×éÍÇѳâä
µèÍÁÒ»Õ¾.È. 2544 ÁÕ¼Ùé»èÇÂ
ÇѳâäãËÁèÍغѵԢÖé¹ 8.5 ÅéÒ¹¤¹
áÅÐàÊÕªÕÇÔµÃèÇÁ 23
ÅéÒ¹¤¹µèͻիÖè§ÊÙ§¡ÇèÒ¡ÒÃÃкҴãËèã¹Í´Õ
µ
â´Â
ÊèǹãËèà¹×èͧ¨Ò¡¡ÒÃÃкҴ¢Í§¡ÒõԴàª×éÍàÍ´Ê
ìáÅÐ
ÇѳâäÂѧ¤§à»ç¹ÊÒà˵ءÒõÒ¢ͧ»ÃЪҡÃÁÒ¡¡ÇèÒâä
µÔ´àª×éÍà´ÕèÂÇÍ×è¹æÑé§ÊÔé
¹
ÁÒ¡¡ÇèÒÃéÍÂÅÐ 95 ¢Í§
»ÃЪҡÃÕèµÒ¹ÕéÍÂÙèã¹»ÃÐàÈÕè¡ÓÅѧ¾Ñ²¹Ò
áÅÐÊͧ
ã¹ÊÒÁ¢Í§¼Ùé»èÇÂÍÂÙèã¹ÇÕ»àÍàªÕ
Â
ÃÇÁ¶Ö§¼Ùé»èǨӹǹ
ÁÒ¡
ÕèäÁè¡Ô¹ÂÒµÒÁÕèá¾Âì¡Ó˹´
â´ÂÁÒ¡ÁÑ¡¡Ô¹ÂÒ
à¾Õ§ 1-2 à´×͹áÅéÇËÂØ´àÁ×èÍàËç¹ÇèÒÍÒ¡ÒôբÖé
¹
à»ç
¹
¼ÅãËéàª×éÍÇѳâäÁÕ¡Òô×éÍÂÒÁÒ¡¢Öé¹àÃ×èÍÂ
æ
áÁéÇèһѨ¨ØºÑ
¹
á¾Âì¨ÐãËé¡ÒÃÃÑ¡ÉÒÇѳâä´éÇÂÂÒ¾ÃéÍÁ¡Ñ¹¶Ö§ 4 ª¹Ô
´
áµèàª×éÍÕèÁÕ¡Òô×éÍÂÒËÅÒ¢¹Ò¹ (multi-drug
resistance) ÁÒ¡¢Öé¹àªè¹à´ÕÂÇ¡Ñ
¹
ÂÔ觡ÇèÒ¹ÕéàÁ×èͻվ.È.
2535 ÂѧÁÕÃÒ§ҹ¡ÒÃÃкҴ¢Í§Çѳâä
Õèàª×éÍ´×éÍÂÒµè
Í
ÂÒËÅÒ¢¹Ò¹ã¹ÊËÃÑ°ÍàÁÃÔ¡Ò
¨¹Í§¤ì¡ÒÃ͹ÒÁÑÂâÅ¡
µéͧ»ÃСÒÈàÁ×èÍà´×͹àÁÉÒ¹
¾.È. 2536 ÇèÒÇѳâä
à»ç¹»ÑËÒ©Ø¡à©Ô¹´éÒ¹ÊØ¢ÀÒ¾ÃдѺâÅ¡4
»ÃÐàÈäÂÁÕ
¼Ùé»èÇÂÇѳâäªØ¡ªØÁÊÙ§à»ç
¹
Íѹ´ÑºÕè 12 ¢Í§âÅ¡
¤×
Í
ÁÕÍѵÃÒ»èÇ 179 ¤¹µè
Í
»ÃЪҡà 1 áʹ¤¹
áÅлÃÐàÈäÂä´é¶Ù¡¨Ñ´à»ç¹ 1
ã¹ 6 »ÃÐàȢͧÇÕ»àÍàªÕÂÕèÁըӹǹ¼Ùé»èÇÂÇѳâä
ÊÙ§ÊØ´Ãͧ¨Ò¡¨Õ
¹
ÍÔ¹à´Õ
Â
ÍԹⴹÕà«Õ
Â
ºÑ§¤ÅÒàÈ
áÅÐ
àÇÕ´¹ÒÁ
¨Ó¹Ç¹¼Ùé»èÇÂÇѳâäÕè¢Öé¹ÐàºÕ¹ãËÁèàÃÔè
Á
áÊ´§á¹Çâ¹éÁà¾ÔèÁ¢Öé¹ËÅѧ»Õ¾.È. 2534 â´ÂÁÒ¡ÕèÊØ
´
ã¹ÀÒ¤à˹×͵͹º¹
µÒÁ´éÇÂÀÒ¤¡ÅÒ§
ÀÒ¤µÐÇѹÍÍ¡
à©Õ§à˹×
Í
áÅÐÀÒ¤ãµé»Ñ¨¨ÑÂÊÓ¤ÑÕèÓãËéÇѳâäá¾Ãè
¡ÃШÒÂä´éàÃç
Ç
ä´éá¡è¤ÇÒÁáÍÍÑ´¢Í§»ÃЪҡÃËÃ×
Í
ªØÁª¹
»ÃЪҡÃäǵèÍàª×é
Í
àªè
¹
»ÃЪҡÃÁÕÀÙÁÔ¤ØéÁ¡Ñ
¹
µè
Ó
à»ç¹àÍ´ÊìËÃ×Íà´ç¡«Öè§ÃкºÀÙÁÔ¤ØéÁ¡Ñ¹ÂѧӧҹäÁè´Õ¾Í
¨ÐäǵèÍ¡ÒõԴàª×é
Í
àª×éÍÇѳâä´×éÍÂÒà»ç¹»ÑËÒ˹Öè§Õè
ÓãËéÇѳâäÃкҴà¾ÔèÁ¢Öé
¹
¨Ò¡¡ÒÃÊÓÃǨà©ÅÕèÂÑè
Ç
»ÃÐàȾºÃéÍÂÅÐ 2.53 àÁ×èͻվ.È. 2539-2541 áµè
ÊÙ§¢Öé¹ã¹éͧÕèÕèÁÕ¡ÒÃÃкҴ¢Í§¡ÒõԴàª×éÍàÍ´ÊìÊÙ
§
àªè
¹
¨Ñ§ËÇÑ´àªÕ§ÃÒÂ
áÅСÃاà¾Ï5
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
ÇÔÇѲ¹Ò¡Òâͧ¡ÒÃÃÑ¡ÉÒÇѳâä
¡è͹¡ÒÃÃÑ¡ÉÒ㹻Ѩ¨ØºÑ
¹
ÁÕ¡ÒôÅͧÃÑ¡ÉÒ
Çѳâä´éÇÂÇÔ¸ÕµèÒ§æ
àªè
¹
¡ÒÃÍÍ¡¡ÓÅѧ¡ÒÂ
¡Òù͹
¹Ôè§äÁèà¤Å×è͹äËÇ
¡ÒÃà»ÅÕ蹶èÒÂàÅ×Í´
¡ÒéմâÅËÐ˹Ñ
¡
µèÒ§æ
àªè
¹
ͧ¤Ó (gold) ¡ÒÃÓãËéà¡Ô´ÅÁÃÑèÇ㹪èͧ
àÂ×èÍËØéÁ»Í´ËÃ×Í㹪èͧàÂ×èÍËØéÁéͧ
¡ÒüèҵѴÅÍ¡àÂ×è
Í
ËØéÁ»Í´
à»ç¹µé
¹
«Öè§äÁè»ÃÐʺ¼ÅÊÓàÃç¨ã¹¡ÒÃÃÑ¡ÉÒ6
¡ÒÃÃÑ¡ÉÒâäÇѳâä
ÁÕ¡ÒþѲ¹ÒÁÒ¨Ò¡ËÅÒÂ
¡ÒÃÈÖ¡ÉÒà»ç¹àÇÅÒÁÒ¡¡ÇèÒ 50 »ÕàÃÔèÁµÑé§áµè»Õ¾Ø¸ÈÑ¡ÃÒª
2481 Rich áÅÐ Follis7 ¨Ò¡ÁËÒÇÔÂÒÅѨÍËì
¹
Î;¡Ô¹Êì (Johns Hopkins University) ´Åͧãªé
ÂÒ«ÑÅ¿Ò¹ÔÅÒäÁ´ì (sulfanilamide) ¢¹Ò´ÊÙ
§
¾ºÇè
Ò
ÊÒÁÒöÂѺÂÑé§àª×éÍÇѳâäã¹Ë¹ÙµÐàÀÒ´Åͧä´éµè
Í
ÁÒ Schatz áÅÐ Waksman ÃÔàÃÔèÁãªéÂÒ streptomycin
ã¹Á¹ØÉÂì¤ÃÑé§áá㹻վ.È. 24878 â´ÂÊ¡Ñ´¨Ò¡àª×éÍÃÒ
Streptomyces griseus µèÍÁÒ»Õ¾.È. 2489 â´Â the
British Medical Research Council (BMRC)
´ÅͧãªéÂÒ streptomycin ÃèÇÁ¡Ñº¡Òù͹¹Ôè§äÁè
à¤Å×è͹äËÇà»ÃÕºàÕº
¡Ñº¡Òù͹¹Ôè§äÁèà¤Å×è͹
äËÇÍÂèÒ§à´ÕÂÇ
㹡ÒÃÃÑ¡ÉÒÇѳâäàÂ×èÍËØéÁÊÁͧáÅÐ
Çѳâä»Í´
¾ºÇèÒà¾ÔèÁÍѵÃÒ¡ÒÃÃÍ´ªÕÇÔµä´éã¹ÃÐÂÐÊÑé
¹
ÍÂèÒ§äáç´ÕÁÕ¡Òô×éÍÂÒÍÂèÒ§ÃÇ´àÃç
Ç
¾ºÇèÒÃéÍÂÅÐ 92 ¢Í§
¼Ùé»èÇÂÕèãªéÂÒ streptomycin ª¹Ô´à´ÕÂǹҹ 3 à´×͹
ÂѧÁÕ¼Åà¾ÒÐàª×éͨҡàÊÁËÐà»ç¹ºÇ¡9 ã¹»Õà´ÕÂÇ¡Ñ
¹
Lehmann ¨Ò¡ÊÇÕà´¹10 ¤é¹¾º¾ÒÃÒÍÐÁÔ⹫ÒÅÔÊÔÅÔ
¡
áÍÊÔ´ (para-aminosalicylic acid, PAS) à¹×èͧ
¨Ò¡¾ºÇèÒ˹Öè§ã¹ÊÒÁ¢Í§¼Ùé»èÇÂÕèãªé PAS ª¹Ô´à´ÕÂÇ
¹Ò¹ 4 à´×͹
ÂѧÁÕ¼Åà¾ÒÐàª×éͨҡàÊÁËÐà»ç¹ºÇ¡
ã¹
»Õ¾.È. 2491 ¨Ö§àÃÔèÁÁÕ¡ÒÃãªéÂÒ streptomycin ¤Ùè¡ÑºÂÒ
PAS â´ÂÊÒÁÒöÓãËé¼ÅàÊÁËÐà»ç¹Åºä´éàÁ×èÍ¡ÒÃ
ÃÑ¡ÉÒ¹Ò¹ 4 à´×͹11 ÍÂèÒ§äáçµÒÁ
Âѧ¾º¡Òô×é
Í
streptomycin ä´éà¡×ͺÃéÍÂÅÐ 10 áÁéÇèÒãªéÃèÇÁ¡Ñº PAS
»Õ¾.È. 2495 ÊÒÁºÃÔÉÑÂÒ
ä´éá¡è Hoffman
LaRoche, ER. Squibb & Sons áÅÐ Bayer àÃÔè
Á
¹ÓÂÒ isoniazid ÁÒãªé«Ö觾ºÇèÒ»ÃÐÊÔ¸ÔÀÒ¾´ÕÁÒ¡
ÃÒ¤Ò
äÁèᾧ
ÃÇÁÑ駼ŢéÒ§à¤Õ§µèÓÍÕ¡´éÇÂ
áÅÐàÁ×è͹ÓÂÒ
isoniazid ãªé¤Ùè¡Ñº streptomycin ¾ºÇèÒ»ÃÐÊÔ¸ÔÀÒ¾
à˹×Í¡ÇèÒ streptomycin áÅÐ PAS µèÍÁÒ»Õ¾.È
2498-2499 ÁÕÍѵÃÒ¡Òô×éÍ streptomycin ÃéÍÂÅÐ 2.5,
PAS ÃéÍÂÅÐ 2.6, isoniazid ÃéÍÂÅÐ 1.3 ¨Ö§àÃÔèÁãªéÂÒ
ÃèÇÁ¡Ñ¹ÁÒ¡¡ÇèÒ 2 ª¹Ô
´
¹Ò¹¶Ö§ 24 à´×͹
à¾×èÍá¡éä¢
àÃ×èͧ¡Òô×éÍÂÒ
Pyrazinamide (PZA) ¶Ù¡¤é¹¾º»Õ¾.È. 2495
àªè¹à´ÕÂǡѺÂÒ isoniazid â´Â Lederle Research
Laboratories ã¹»Õ¾.È. 2503 ÁÕ¡Òä鹾º rifampicin
«Öè§à»ç¹ÂÒÃѺ»ÃÐÒ¹ÕèÁÕĸ
ìÔ¦èÒàª×éÍÇѳâäÕè
ÁÕ
»ÃÐÊÔ¸ÔÀÒ¾
ÓãËéÊÒÁÒöŴÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒ¨Ò¡
18-24 à´×͹
àËÅ×Íà¾Õ§ 6 à´×͹
â´ÂäÁèà¾Õ§áµèËÒÂ
¢Ò´
áµèÂѧ»éͧ¡Ñ¹¡ÒáÅѺà»ç¹«éӢͧâä12 ÊèǹÂÒ
Ethambutol (EMB) ¶Ù¡¤é¹¾º»Õ¾.È. 2504 ¨ÐàËç
¹
ä´éÇèÒÂؤͧ¢Í§¡ÒäԴ¤é¹ÂÒÃÑ¡ÉÒÇѳâäÍÂÙè㹪èǧ
ÈÇÃÃɹÕé
㹨ѧËÇÑ´ Madras ã¹»ÃÐàÈÍÔ¹à´Õ
Â
ÁÕ¡ÒÃ
ÃÔàÃÔèÁ¡ÒÃÃÑ¡ÉÒ¼Ùé»èÇÂÇѳâäÕèºéÒ¹
¾ºÇèÒä´é¼Åà»ç¹Õè¹è
Ò
¾Íã¨
áÅÐäÁèà¾ÔèÁ¡ÒõԴàª×éͧ͢¤¹ã¹¤Ãͺ¤ÃÑÇÕèÍÂÙè
ÃÇÁ¡Ñº¼Ùé»èÇ´éÇÂ
ÍÂèÒ§äáç
´ÕµèÍÁÒÁÕ¡ÒÃãªéá¹Ç¤ÇÒÁ
¤Ô´ directly observed therapy (DOTS) ã¹»Õ¾.È.
2501 à¾×èÍãËé¼Ùé»èÇÂÃѺ»ÃÐÒ¹¤Ãº¶éǹÁÒ¡¢Öé
¹
ÂÒÕèÁÕ»ÃÐÊÔ¸ÔÀҾ㹡ÒæèÒàª×éÍÇѳâäã¹
»Ñ¨¨ØºÑ
¹
áÅÐä´éÃѺ¡ÒÃÂÍÁÃѺâ´Â
ͧ¤ì¡ÒÃÍÒËÒÃáÅÐ
ÂÒ (Food and Drug Administration, FDA) ¢Í§
ÊËÃÑ°ÍàÁÃÔ¡Ò
àªè¹ isoniazid, pyrazinamide,
rifampicin, ethambutol, rifapentine, cycloserine,
ethionamide, capreomycin, PAS áÅÐ
streptomycin ÊèǹÂÒÕèäÁèä´éÃѺ¡ÒÃÂÍÁÃѺâ´Âͧ¤ì¡ÒÃ
ÍÒËÒÃáÅÐÂÒáµè¼ÙéàªÕèÂǪÒá¹Ð¹ÓãËéãªéä´éàªè
¹
rifabutin aminoglycosides (amikacin,
kanamycin), fluoroquinolones (ciprofloxacin,
moxifloxacin, levofloxacin) (µÒÃÒ§Õè 1)
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
µÒÃÒ§Õè 1. áÊ´§ÂÒÃÑ¡ÉÒÇѳâäÕèÁÕãªé㹻Ѩ¨ØºÑ¹ã¹»ÃÐàÈÊËÃÑ°ÍàÁÃÔ¡Ò
First-line drugs
Isoniazid
Rifampin
Rifapentine
Rifabutin*
Ethambutol
Pyrazinamide
Streptomycin
Second-line drugs
Cycloserine
Ethionamide
Levofloxacin*
Moxifloxacin*
Gatifloxacin*
Para-aminosalicylic acid
Amikacin/kanamycin*
Capreomycin
* äÁèä´éÃѺ¡ÒÃÂÍÁÃѺ¨Ò¡Í§¤ì¡ÒÃÍÒËÒÃáÅÐÂÒ (Food and Drug Administration, FDA)
ËÅÑ¡¡ÒÃÃÑ¡ÉÒÇѳâäẺÃÐÂÐÊÑé¹ (shortcourse
chemotherapy) ÃÒ§ҹ¤ÃÑé§ááã¹á¶º
áÍ¿ÃÔ¡ÒµÐÇѹÍÍ¡13 â´Âà»ÃÕºàÕºÃÐÂÐàÇÅÒ¡ÒÃ
ÃÑ¡ÉÒ 6 à´×͹
´éÇ streptomycin áÅÐ isoniazid,
streptomycin, isoniazid áÅÐ rifampicin,
streptomycin, isoniazid áÅÐ pyrazinamide,
streptomycin, isoniazid and thioacetazone ¡Ñ
º
ÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒ 18 à´×͹
´éÇÂÂÒ isoniazid áÅÐ
thioacetazone ¼Å¡ÒÃÃÑ¡ÉÒ¾ºÇèÒ¡ÒÃãªéÂÒ 3 ª¹Ô
´
¤×Í streptomycin, isoniazid áÅÐ rifampicin ÊÒÁÒö
à»ÅÕè¹àÊÁËÐà»ç¹ÅºÕèÃÐÂÐàÇÅÒÊÔé¹ÊØ´¡ÒÃÃÑ¡ÉÒ
áÅÐ
¡ÒÃÍѵÃÒ¡ÅѺà»ç¹«éÓà¾Õ§ÃéÍÂÅÐ 314
㹻Ѩ¨ØºÑ¹¤ÇÒÁàËç¹ã¹àÃ×èͧ¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
ÕèàËÁÒÐÊÁÕèÊØ´¨ÐµÃ§¡Ñ¹ÑèÇâÅ¡
¡ÅèÒǤ×
Í
ÁÕá¹ÇÒ§
àʹÍá¹Ð
â´Â¡ÅØèÁ¼ÙéàªÕèÂǪÒã¹»ÃÐàÈÕè¾Ñ²¹ÒáÅé
Ç
àªè
¹
ÊËÃÑ°ÍàÁÃÔ¡Ò (American Thoracic Society
¾.È. 2537) ¡ÑºÊËÃÒªÍҳҨѡà (British Thoracic
Society ¾.È. 2540) áÅÐÕèàʹÍá¹Ðâ´Âͧ¤ì¡ÒùҹÒ
ªÒµÔä´éá¡èͧ¤ì¡ÒÃ͹ÒÁÑÂâÅ¡ (WHO Tuberculosis
Unit ¾.È. 2540) áÅÐ International Union Against
Tuberculosis and Lung Disease (IUATLD ¾.È.
2540) Êͧͧ¤ì¡ÃËÅѧà»ç¹á¹ÇÒ§ÕèÁØè§à¹é¹ÊÓËÃÑ
º
»ÃÐàÈÕè¡ÓÅѧ¾Ñ²¹ÒÕèÂѧÁÕÇѳâäªØ¡ªØ
Á
©Ð¹Ñ鹨֧¡ÅèÒÇ
ä´éÇèÒ¡ÒÃÃÑ¡ÉÒÃÐÂÐÊÑé¹Õèãªé㹻Ѩ¨ØºÑ¹à»ç¹ÃкºÂÒÃдÑ
º
¹Ò¹ÒªÒµÔËÃ×ÍÃдѺâÅ¡
ÕèÁÕ»ÃÐÊÔ¸ÔÀÒ¾áÅÐ
»ÃÐÊԸԼŴÕÕèÊØ
´
Õè¨ÐÃÑ¡ÉÒ¼Ùé»èÇÂÇѳâäãËéËÒÂä´é
à¡×ͺÃéÍÂÅÐ 100 ¶éÒ¼Ùé»èÇÂä´éÃѺÂÒÊÁèÓàÊÁͤú¶éǹ
ÂÒÃÑ¡ÉÒÇѳâä15,16,17,18
äÍâ«ä¹ÍÐÊÔ´ (isoniazid)
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
ÂÒäÍâ«ä¹ÍÐÊÔ´ (isoniazid) àÃÔèÁ¹ÓÁÒãªéã¹
»Õ¾.È. 2495 ãªéÃÑ¡ÉÒÑ駡ÒõԴàª×éÍËź«è͹áÅСÒÃ
µÔ´àª×éÍẺáÊ´§ÍÒ¡ÒÃ
Í͡ĸìԢѴ¢ÇÒ§¡ÒÃÊÃéÒ§¡Ã´
äÁâ¤ÅÔ¡ (mycolic acid)19 ã¹¢Ñ鹵͹Õèµéͧãªé
ÍÍ¡«Ôਹ
«Ö觡ôäÁâ¤ÅÔ¡à»ç¹¡Ã´ä¢Áѹ¢¹Ò´ÂÒÇ«Öè
§
Êèǹ»ÃСͺ¢Í§¼¹Ñ§à«ÅÅì (ÀÒ¾Õè 1) ÂÒäÍâ«ä¹
ÍÐÊÔ´¦èÒàª×éÍÕè¡ÓÅѧáºè§µÑÇä´éÍÂèÒ§ÃÇ´àÃç
Ç
ºÃÔËÒÃÂÒ
â´Â¡ÒÃÃѺ»ÃÐÒ¹
ÍÒ¨ãªé©Õ´à¢éÒ¡ÅéÒÁà¹×éÍËÃ×Íà¢é
Ò
ËÅÍ´àÅ×Í´´Óä´é¢¹Ò´»¡µÔ 3-5 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹Ñ
¡
µÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¢¹Ò´ÂÒÊÙ§ÊØ´ 300 ÁÔÅÅÔ¡ÃÑÁµè
Í
ÇÑ
¹
ÃдѺÂÒÊÙ§ÊØ´ 1-2 ªÑèÇâÁ§
ËÅѧÃѺ»ÃÐÒ¹
ÃдÑ
º
ÂÒÍÒ¨¶Ù¡´Ù´«ÖÁ¹éÍÂŧËÒ¡ÃѺ»ÃÐÒ¹ÃèÇÁ¡Ñº¹éÓµÒÅ
¡ÅÙâ¤ÊËÃ×ÍáÅ¡âµÊ
ÂÒ¼èÒ¹à¢éÒÃкº»ÃÐÊÒÊèǹ¡ÅÒ§
ä´é
´Õ¶Ù¡¡Ó¨Ñ´Ò§µÑºâ´ÂÇÔ¸ÕÍÐ૵ÔàŪÑè¹ (acetylation)
â´ÂäÁèÁÕ¤ÇÒÁÊÑÁ¾Ñ¹¸ìÃÐËÇèÒ§ÃдѺÂÒã¹àÅ×Í´áÅСÒÃ
à»ç¹¾Ôɵè͵Ñ
º
ÀÒ¾Õè 1 áÊ´§µÓá˹觡ÒÃÍ͡ĸìԢͧÂÒ20
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
¼Å¢éÒ§à¤Õ§¢Í§ÂÒäÍâ«ä¹ÍÐÊÔ
´
ÓãËéÃдÑ
º
»ÃÐÁÒ³ÃéÍÂÅÐ 1 µèÍ»Õ23 ¨Ò¡¡ÒÃÈÖ¡ÉҢͧ Steele
à͹ä«ÁìÍÐÁÔâ¹ÃÒ¹à¿ÍàÃÊ (aminotranferases) à¾Ôè
Á
ÊÙ§¢Öé¹ä´é¶Ö§ 5 àèҢͧ¤èÒ»¡µÔâ´ÂäÁèÁÕÍÒ¡ÒÃÒ§¤ÅÔ¹Ô
¡
¾º»ÃÐÁÒ³ÃéÍÂÅÐ 10-20 áÅÐÊÒÁÒö¡ÅѺŧÊÙèÃдÑ
º
»¡µÔä´éàͧ
â´ÂäÁèµéͧËÂØ´ÂÒ
µÑºÍÑ¡àʺ¨Ò¡ÂÒäÍâ«ä¹ÍÐÊÔ´á¡ÂÒ¡¨Ò¡µÑ
º
ÍÑ¡àʺ¨Ò¡àª×éÍäÇÃÑ
Ê
Ñ駨ҡÍÒ¡ÒÃáÅоÂÒ¸ÔÇÔÂҢͧ
µÑ
º
¨Ò¡ÃÒ§ҹ¢Í§ Black áÅФ³Ð21 ÈÖ¡ÉÒ¼Ùé»èÇÂ
114 ¤¹
¾ºÇèÒÁÒ¡¡ÇèÒ¤ÃÖè§ÁÕÍÒ¡ÒÃÒ§ÃкºÒ§à´Ô
¹
ÍÒËÒÃÕèäÁè¨Óà¾ÒÐà¨ÒШ§
ÍÒ¡ÒäÅéÒµԴàª×éÍäÇÃÑ
Ê
¾º»ÃÐÁÒ³ÃéÍÂÅÐ 35 ËÅѧ¨Ò¡¹Ñé¹ËÅÒÂÇѹ¨¹¶Ö§ËÅÒÂ
ÊÑ»´ÒËì¨Ö§ÁÕÍÒ¡ÒÃàËÅ×ͧµÒÁÁÒ
ÊèǹÍÒ¡ÒÃàËÅ×ͧÕèà»ç
¹
ÍÒ¡ÒùӾºá¤èÃéÍÂÅÐ 10 â´Âà¡×ͺÃéÍÂÅÐ 50 ¾ºã¹
ªèǧ 2 à´×͹áá¢Í§¡ÒÃÃѺ»ÃÐÒ¹ÂÒ
áµèºÒ§ÃÒÂÍÒ¨
¾ºä´é¹Ò¹¶Ö§ 14 à´×͹
¨Ò¡ÃÒ§ҹ»Õ¾.È. 251522 ¾º¼Ùé
àÊÕªÕÇÔµ 2 ÃÒÂ
µèÍÁÒÈÙ¹Âì¤Çº¤ØÁáÅлéͧ¡Ñ¹âäµÔ´µè
Í
ÃÒ§ҹÇèÒÁÕ
¼Ùé»èǵѺÍÑ¡àʺ¨Ò¡ÂÒäÍâ«ä¹ÍÐÊÔ
´
áÅФ³Ð24 (µÒÃÒ§Õè 2) ã¹»Õ¾.È. 2503-2523 ¾ºÇè
Ò
ÍѵÃÒ¡ÒÃà¡Ô´µÑºÍÑ¡àʺÃéÍÂÅÐ 0.6 Êèǹ Nolan áÅÐ
¤³Ð25 Ó¡ÒÃÊÓÃǨ 7 »Õ¾ºà¾Õ§ÃéÍÂÅÐ 0.1-0.3 ÍÂèÒ§
äáç
´Õ¾ºµÑºÍÑ¡àʺä´éÁÒ¡¢Ö鹶֧ÃéÍÂÅÐ 2.7 ¶éÒãªéÃèÇÁ
¡ÑºÂÒäÃá¿Á¾Ô«Ô¹ (rifampicin) ¹Í¡¨Ò¡¹ÕéÂѧ¾ºà¾Ôè
Á
¢Öé¹ã¹¼ÙéÊÙ§ÍÒÂØâ´Â੾ÒÐÍÂèÒ§ÂÔè§ÍÒÂØÁÒ¡¡ÇèÒ 65 »Õ
¾º»ÃÐÁÒ³ÃéÍÂÅÐ 4.6 âäµÑºáÅмÙé´×èÁÊØÃÒà»ç¹»ÃШÓ
¾º»ÃÐÁÒ³ÃéÍÂÅÐ 2.6 »Ñ¨¨ÑÂàÊÕè§Í×è¹æ
ä´éá¡èËÔ
§
µÑ駤ÃÃÀ
ìËÃ×ͼÙéÕèÃѺ»ÃÐÒ¹ÂÒÕè¡ÃеØ鹡ÒÃÓ§Ò¹¢Í§
ä«âµâ¤ÃÁ¾Õ (cytochrome P 450) àªè
¹
ÂҡѹªÑ¡ä´
áŹµÔ¹ (dilantin) ´Ñ§¹Ñ鹤ÇÃãªéÂÒ´éǤÇÒÁÃÐÁÑ´ÃÐÇÑ
§
ËÁÑè¹µÃǨ¡ÒÃÓ§Ò¹¢Í§µÑºØ¡à´×͹ËÃ×ÍàÁ×èÍàÃÔèÁÁÕ
ÍÒ¡ÒÃ
ËÂØ´ÂÒàÁ×èÍÃдѺà͹ä«ÁìÍÐÁÔâ¹ÃÒ¹à¿ÍàÃÊ
(aminotranferases) à¾ÔèÁÊÙ§¢Öé¹ÁÒ¡¡ÇèÒ 3-5 àèҢͧ
¤èÒ»¡µÔ
µÒÃÒ§Õè 2 áÊ´§¡ÒÃà¡Ô´µÑºÍÑ¡àʺ¨Ò¡ÂÒäÍâ«ä¹ÍÐÊÔ´24
âä¢Í§àÊé¹»ÃÐÊÒÊèǹ»ÅÒÂÊÑÁ¾Ñ¹¸ì¡Ñº¢¹Ò´
¢Í§ÂÒäÍâ«ä¹ÍÐÊÔ
´
¾º¹éÍ¡ÇèÒÃéÍÂÅÐ 0.2 ¶éÒãªéÂÒ
¢¹Ò´»¡µÔÁÑ¡à¡Ô´ã¹¼ÙéÕèÁջѨ¨ÑÂàÊÕ觵èÍ¡ÒÃà¡Ô´âä¢Í§
àÊé¹»ÃÐÊÒÊèǹ»ÅÒÂÍÂÙèà´Ô
Á
¼ÙéÕè¢Ò´ÇÔµÒÁÔ
¹
´×èÁÊØÃÒ
àºÒËÇÒ¹
âääµ
ËÔ§µÑ駤ÃÃÀìËÃ×ÍàÅÕ駺صôéǹéÓ¹Á
¡ÒÃãËéÇÔµÒÁÔ¹ºÕË¡ (pyridoxine) ¢¹Ò´ 25 ÁÔÅÅÔ¡ÃÑ
Á
µèÍÇÑ
¹
ªèÇ»éͧ¡Ñ¹¡ÒÃà¡Ô´ä´é
ÁÕÃÒ§ҹ¡ÒÃà¡Ô´»‾Ô¡ÔÃÔÂҵͺʹͧ¤ÇÒÁäǵè
Í
ÂÒ
àªè
¹
ä¢é¼×蹤Ñ
¹
ʵÕàǹ
¨ÍËì¹Êѹ (Stevens Johnson
syndrome) àÁç´àÅ×Í´¢Òǵè
Ó
àÁç´àÅ×ʹᴧᵡ§èÒÂ
»Ç´¢é
Í
ªÑ
¡
ÍÒ¡ÒÃÒ§Ãкº»ÃÐÊÒ
ËÃ×ÍÅѡɳÐ
¤ÅéÒÂâäÅÙ»Ñ
Ê
¾ºá͹µÔºÍ´ÕéµèÍÀÙÁÔ¤ØéÁ¡Ñ¹µÑÇàͧ (antinuclear
antibodies) ä´é¶Ö§ÃéÍÂÅÐ 20 ¾º¡ÒÃà¡Ô´ÍÒ
¡ÒÃâäÅÙ»ÑÊä´é¹éÍ¡ÇèÒÃéÍÂÅÐ 1 áµèËÒ¡à¡Ô´µéͧËÂØ
´
ÂÒѹÕ
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
ºÒ§ÃÒ§ҹ¾ºÇèÒËÒ¡ÃѺ»ÃÐÒ¹ÍÒËÒÃÕèÁÕÊèǹ
»ÃСͺ¢Í§âÁâ¹àÍÁÕ¹ (monoamine) àªè
¹
äǹ
ìÍÒ¨
ÓãËéÃдѺâÁâ¹àÍÁÕ¹ÊÙ§¨¹à¡Ô´ÍÒ¡ÒÃà»ç¹¾ÔÉä´é
»‾Ô¡ÔÃÔÂҡѺÂÒÍ×è
¹
ä´éá¡èà¾ÔèÁÃдѺÂҡѹªÑ
¡
¿Õ¹ÔÅâµÍÔ¹ (phenytoin) áÅÐ
¤ÒºÒÁÒ«Õ»Ô
¹
(carbamazepine) ´Ñ§¹Ñé
¹
ÍÒ¨µéͧµÃǨÃдѺÂÒ¡Ñ
¹
ªÑ¡ã¹àÅ×Í´à¾×èÍ»ÃѺ¢¹Ò´ÂÒ
äÿÒäÁ«Ô¹ (rifamycins)
äÿÒäÁ«Ô
¹
»ÃСͺ´éÇÂ
äÃá¿Á»Ô
¹
(rifampin) äÿҺٵԹ (rifabutin) áÅÐ
äÿÒà¾ç
¹
µÔ¹ (rifapentine) à»ç¹ÂÒµÑÇÊÓ¤Ñ㹡ÒÃÃÑ¡ÉÒÇѳâä
Ø¡ÃٻẺáÅШÓà»ç¹µÅÍ´ÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒ
ÍÍ¡
ĸìԢѴ¢ÇÒ§¡ÒÃÊÃéÒ§äÃ⺹ÔǤÅÕÍÔ¤áÍÊÔ´ (RNA)
ã¹¢Ñ鹵͹ transcription â´Â¨Ñº¡ÑºÊèǹີéÒ (.subunit
of RNA polymerase) (ÀÒ¾Õè 1) ¦èÒàª×é
Í
ÇѳâäÑ駢³ÐÕè¡ÓÅѧáºè§µÑÇÍÂèÒ§ÃÇ´àÃçÇáÅÐàª×éÍÕè
ʧºÍÂÙ袹Ҵ¢Í§äÃá¿Á»Ô¹ã¹¼ÙéãËè 10 ÁÔÅÅÔ¡ÃÑ
Á
µè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¢¹Ò´ÊÙ§ÊØ´ 600
ÁÔÅÅÔ¡ÃÑÁµèÍÇÑ
¹
äÃá¿Á»Ô¹ÓãËéà»ÅÕè¹ÊÕÊÒäѴËÅÑè
§
µèÒ§æ¢Í§ÃèÒ§¡ÒÂ
àªè
¹
¹éÓµÒ
à˧×è
Í
»ÑÊÊÒÇÐ
ËÃ×ÍáÁé
áµèÊդ͹á¤àŹÊ
ì¼Å¢éÒ§à¤Õ§Í×è¹æ
ä´éá¡è¼×蹤Ñ
¹
(ÃéÍÂÅÐ 6) ¤Å×è¹äÊééͧàÊÕ
Â
»Ç´éͧ
ÍÒ¨¾ºÃдÑ
º
ºÔÅÔÃÙºÔ¹ÊÙ§¢Öé¹ä´éªÑèǤÃÒÇ (ÃéÍÂÅÐ 0.6) «Öè§ÍÒ¡ÒÃàËÅè
Ò
¹ÕéÁÑ¡äÁè¨Óà»ç¹µéͧËÂØ´ÂÒ
ÂÒäÃá¿Á»Ô¹ÓãËéà¡Ô´µÑ
º
ÍÑ¡àʺ¹éÍÂÁÒ¡
à¡×ͺÃéÍÂÅÐ 0 ËÒ¡ãªéÃèÇÁ¡ÑºÂÒäÍ
â«ä¹ÍÐÊÔ
´
¨Ðà¾ÔèÁ¡ÒÃà¡Ô´µÑºÍÑ¡àʺä´é¶Ö§ÃéÍÂÅÐ 2.7
áµèËÒ¡ãªéÃèÇÁ¡ÑºÂÒÍ×è¹ÕèäÁèãªèäÍâ«ä¹ÍÐÊÔ
´
¨Ðà¾ÔèÁ¡ÒÃ
à¡Ô´µÑºÍÑ¡àʺÃéÍÂÅÐ 1.1
ËÒ¡ãªéÂÒäÃá¿Á»Ô¹à¡Ô¹¢¹Ò´Õè¡Ó˹´
ËÃ×Íãªé
ÂÒẺ 2-3 ¤ÃÑ駵èÍÊÑ»´ÒË
ìÍÒ¨à¡Ô´ÍÒ¡ÒäÅéÒÂä¢éËÇÑ
´
ãËèÍÔ¹¿ÙàÍ繫èÒ (influenza) ä´é»ÃÐÁÒ³ÃéÍÂÅÐ 0.4
0.7 ¤×
Í
ÁÕä¢é˹ÒÇÊÑè
¹
»Ç´ÈÕÃÉÐ
»Ç´àÁ×è͵ÒÁµÑ
Ç
»Ç´¢é
Í
ÍÒ¡ÒÃàËÅèÒ¹ÕéÁÑ¡à¡Ô´ËÅѧÃѺ»ÃÐÒ¹ÂÒ 1-2
ªÑèÇâÁ§
áÅÐÍÒ¨¹Ò¹¶Ö§ 8 ªÑèÇâÁ§
àª×èÍÇèÒà»ç¹»‾Ô¡ÔÃÔÂÒ
µÍºÊ¹Í§Ò§ÃкºÀÙÁÔ¤ØéÁ¡Ñ
¹
¾ºã¹¼ÙéÕèÃѺ»ÃÐÒ¹ÂÒ
à»ç¹ªèǧæÁÒ¡¡ÇèÒ¡ÒÃÃѺ»ÃÐÒ¹ÂÒØ¡ÇÑ
¹
â´Âà¡Ô´ä´é
Ø¡àÇÅÒã¹ÃÐËÇèÒ§¡ÒÃÃÑ¡ÉÒ
áµèÁÑ¡¾ºËÅѧ¨Ò¡ÃÑ
º
»ÃÐÒ¹ä»áÅéÇ»ÃÐÁÒ³ 3-6 à´×͹ Grosset áÅÐ
¤³Ð26 à»ÃÕºàÕº¡ÒÃÃѺ»ÃÐÒ¹ÂÒäÃá¿Á»Ô
¹
¾ºÇè
Ò
¶éÒÃѺ»ÃÐÒ¹¢¹Ò´ 1200-1800 ÁÔÅÅÔ¡ÃÑ
Á
µèÍÊÑ»´ÒË
ì
à¡Ô´ÍÒ¡ÒäÅéÒÂÍÔ¹¿ÙàÍ繫èÒÃéÍÂÅÐ 35-57 ¶éÒÃѺ»ÃÐÒ¹
¢¹Ò´ 900 ÁÔÅÅÔ¡ÃÑÁµèÍÊÑ»´ÒË
ìà¡Ô´ÍÒ¡ÒäÅéÒÂÍÔ¹¿ÙàÍç
¹
«èÒÃéÍÂÅÐ 22-31 áÅÐà¡Ô´à¾Õ§ÃéÍÂÅÐ 10 ¶éÒÃѺ»ÃÐÒ¹
¢¹Ò´ 600 ÁÔÅÅÔ¡ÃÑÁµèÍÊÑ»´ÒË
ì
»‾Ô¡ÔÃÔÂҵͺʹͧҧÀÙÁÔ¤ØéÁ¡Ñ
¹
àªè
¹
à¡Ãç´àÅ×Í´
µè
Ó
«Õ´¨Ò¡àÁç´àÅ×ʹᴧᵡ
à¡Ô´¹éÍÂÁÒ¡¡ÇèÒÃéÍÂÅÐ
0.1
ÂÒäÃá¿Á»Ô¹ÁÕ»‾Ô¡ÔÃÔÂÒµèÍÂÒÍ×è¹æÁÒ¡ÁÒÂ
à¹×èͧ
¨Ò¡à»ç¹µÑÇ¡ÃеØ鹡ÒÃÓ§Ò¹¢Í§à͹ä«ÁìµèÒ§æÕèáç
àªè
¹
¡ÃеØé¹ä«âµâ¤ÃÁ
¾Õ 450 (cytochrome P 450)
Å´ÃдѺÂÒ¤ØÁ¡Óà¹Ô´ã¹¡ÃÐáÊàÅ×Í´
à¾ÔèÁ¡ÒâѺàÁ
Òâ´¹ (methadone) ÓãËéà¡Ô´ÍÒ¡Òö͹ÂÒ
áÅÐ
à¾ÔèÁ¡ÒâѺ¡ÅÙ⤤͵ԤÍ´ì (glucocorticoids) ÓãËé
à¡Ô´µèÍÁËÁÇ¡äµÓ§Ò¹µèÓä´é´Ñ§¹Ñ鹤ÇÃÃÐÇѧ㹡ÒÃãªé
ÂÒÍ×è¹ÃèÇÁ¡ÑºÂÒäÃá¿Á»Ô
¹
ÂÒãËÁèÍÕ¡µÑÇ˹Öè
§
㹡ÅØèÁäÿÒäÁ«Ô
¹
¤×
Í
äÃ
¿ÒÅÒ«ÔÅ (rifalazil, RLZ) (KRM1648 ËÃ×
Í
benzoxazinorifamycin) à»ç¹ÂÒ¡Öè§Êѧà¤ÃÒÐËìÕèÍÍ¡
ĸìÔ¹Ò¹
¨Ò¡¡ÒôÅͧã¹Ë¹Ù27 ¾ºÇèÒÁÕ»ÃÐÊÔ¸ÔÀÒ¾
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
´Õ¡ÇèÒäÃá¿Á¾Ô«Ô¹áÅÐäÿҺٵÔ
¹
Êèǹ㹤¹¾ºÇèÒÂÒäÃ
¿ÒÅÒ«ÔÅÍÒ¨ÓãËéà¡Ô´¼Å¢éÒ§à¤Õ§¤ÅéÒÂä¢éËÇÑ´ãËèÅ´
¨Ó¹Ç¹àÁç´àÅ×Í´¢ÒÇáÅÐà¡Ãç´àÅ×Í´ªÑèǤÃÒÇ
áµè
»ÃÐÊÔ¸ÔÀÒ¾äÁèä´é´Õ¡ÇèÒÂÒäÃá¿Á¾Ô«Ô
¹
´Ñ§¹Ñ鹡ÒÃãªéÂÒ
äÿÒÅÒ«ÔŤ§µéͧÃÍ¡ÒÃÈÖ¡ÉÒÍ×è¹ÁÒʹѺʹعà¾ÔèÁàµÔ
Á
¾ÑÂÃÒ«Ô¹ÒäÁ´ì (pyrazinamide)
¾ÑÂÃÒ«Ô¹ÒäÁ´ì (pyrazinamide) à»ç¹ÂÒÍա˹Öè
§
ª¹Ô´ã¹¡ÅØèÁÂÒËÅѡ㹡ÒÃÃÑ¡ÉÒÇѳâäءÃٻẺ
ú¡Ç¹¡Òâ¹Ê觢ͧàÂ×èÍËØéÁà«ÅÅìáÅТѴ¢ÇÒ§¡ÒÃÊÃéÒ§
¾Åѧ§Ò¹ã¹Êèǹ¢Í§¡Ã´ä¢Áѹ¢¹Ò´ÊÑé¹ (short-chain,
fatty-acid precursors) (ÀÒ¾Õè 1) ¢¹Ò´ã¹¼ÙéãËè
20-25 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ÂÒ
ÊÒÁÒö¼èÒ¹à¢éÒÃкº»ÃÐÊÒÊèǹ¡ÅÒ§ä´é
´ÕÃдѺÂÒ
ã¹¹éÓä¢ÊѹËÅѧàèҡѺ㹡ÃÐáÊàÅ×Í´
¶Ù¡¡Ó¨Ñ´â´ÂµÑ
º
áµè¢ÑºÍÍ¡Ò§»ÑÊÊÒÇÐ
ÃдѺÂÒÍÒ¨ÊÐÊÁËÒ¡¼Ùé»èÇÂ
äµÇÒÂ
´Ñ§¹Ñ鹤ÇÃÅ´¢¹Ò´ÂÒŧàËÅ×Í 25-35 ÁÔÅÅÔ¡ÃÑ
Á
µè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ÊÒÁÇѹµèÍÊÑ»´ÒËìÍÒ¡ÒÃ
¢éÒ§à¤Õ§
ä´éá¡è¼×è
¹
¤Å×è¹äÊéÍÒà¨Õ¹
àº×èÍÍÒËÒÃ
¡Ã´
ÂÙÃÔ¤ã¹àÅ×Í´ÊÙ
§
¡ÒÃà»ç¹¾Ôɵè͵Ñ
º
ÍÂèÒ§äáç´Õà¡Ô´¾Ô
É
µè͵Ѻ¹éÍÂÁÒ¡
ËÒ¡ãªéÂÒ¢¹Ò´¹éÍ¡ÇèÒ 25 ÁÔÅÅÔ¡ÃÑ
Á
µè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¨Ò¡¡ÒÃÈÖ¡ÉÒ
¼Ùé»èÇÂ
430 ÃÒÂ
¢Í§
Yee áÅФ³Ð28 ã¹»Õ¾.È. 2533 ¶Ö
§
2542 ¾ºÇè
Ò
¾ÑÂÃÒ«Ô¹ÒäÁ´ì¡èÍãËéà¡Ô´¼Å¢éÒ§à¤Õ§´éÒ¹
µÑºÍÑ¡àʺáÅм×è¹ÁÒ¡¡ÇèÒÂÒËÅÑ¡µÑÇÍ×è¹æ (¾ÑÂÃÒ«Ô¹Ò
äÁ´ìÃéÍÂÅÐ 6 äÍâ«ä¹ÍÐÊÔ´ÃéÍÂÅÐ 4 äÃá¿Á»Ô¹ÃéÍÂ
ÅÐ 3) â´Â¾ºÁÒ¡ã¹à¾ÈËÔ
§
ÍÒÂØÁÒ¡¡ÇèÒË¡ÊÔº»Õ
àª×éͪҵÔàÍàªÕ
Â
áÅÐÀÒÇÐÀÙÁÔ¤ØéÁ¡Ñ¹º¡¾Ãèͧ
ÍÒ¡ÒûǴ
µÒÁ¢é;ºä´ééÃéÍÂÅÐ 40 «Ö觵ͺʹͧµèÍ¡ÒÃãËéÂÒµéÒ¹
¡ÒÃÍÑ¡àʺÕèäÁèãªèÊàµÕÂÃÍ´
ìâ´ÂäÁè¨Óà»ç¹µéͧËÂØ´ÂÒ
ÍÕáÁºÙÍÅ (ethambutol)
ÍÕáÁºÙÍÅ (ethambutol) à»ç¹ÂÒËÅѡ㹡ÒÃ
ÃÑ¡ÉÒÇѳâäءÃٻẺ
ãªéªèÇ»éͧ¡Ñ¹¡Òô×éÍÂÒ
äÃá¿Á»Ô
¹
àÁ×èÍà¡Ô´¡Òô×é͵èÍÂÒäÍâ«ä¹ÍÐÊÔ´áÅé
Ç
µÑé§áµèáá
ÂѺÂÑ駡ÒÃÊÃéÒ§ÍÐÃÒºÔ⹡ÒáŤᵹ¢Í§¼¹Ñ
§
à«ÅÅìÂÒ¼èÒ¹à¢éÒàÂ×èÍËØéÁÊÁͧÕèÁÕ¡ÒÃÍÑ¡àʺä´éáµèäÁèÁÕ¡ÒÃ
ÃÒ§ҹ»ÃÐÊԸԼŵèÍ¡ÒÃÃÑ¡ÉÒÇѳâäàÂ×èÍËØéÁÊÁͧ29
¢¹Ò´ÂÒã¹¼ÙéãËè 15-20 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1
¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ÂÒ¶Ù¡¢ÑºÍÍ¡Ò§äµ
´Ñ§¹Ñ鹤ÇÃÅ´¢¹Ò´
ÂÒŧàÁ×èͤèÒ¡ÒáӨѴ¤ÃÕÍеԹÕ
¹
¹éÍ¡ÇèÒ 20 ÁÔÅÅÔÅÔµÃ
µè͹ÒռŢéÒ§à¤Õ§¢Í§ÂÒÍÕáÁºÙÍÅ
ä´éá¡èÅ´
ÃдѺ¡ÒÃÁͧàËç¹áÅÐÊÙàÊÕ¡ÒÃá¡áÂÐÊÕá´§áÅÐÊÕ
à¢ÕÂÇ
¢Ö鹡Ѻ¢¹Ò´ÂÒÕèãªé (¾ºÃéÍÂÅÐ 18 àÁ×èÍãªé¢¹Ò´
ÂÒÁÒ¡¡ÇèÒ 30 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµè
Í
Çѹ) â´ÂÍÒ¨à¡Ô´Ë¹Öè§ËÃ×ÍÑé§ÊͧµÒ¡çä´é¨Ö§äÁè¹ÔÂÁãªé
ã¹à´ç
¡
à¹×èͧ¨Ò¡äÁèÊÒÁÒöà½éÒÃÐÇѧä´é Leibold30 ¾ºÇè
Ò
äÁèÁÕ¤ÇÒÁᵡµèҧ㹡ÒÃà¡Ô´»ÑËÒ¡ÒÃÅ´ÃдѺ¡ÒÃÁͧ
àËç
¹
àÁ×èÍà»ÃÕºàÕºÃÐËÇèÒ§¡ÒÃãªéÂÒÍÕáÁºÙÍÅ
¢¹Ò´ 15 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¡Ñº¡ÒÃäÁèãªéÂÒÍÕáÁºÙÍÅ
ÍÂèÒ§äáçµÒÁ¤ÇõÃǨ
ÃдѺÊÒÂµÒ (Snellen chart) áÅСÒÃá¡áÂÐÊÕ
(Ishihara tests) äÇéà»ç¹¾×é¹°Ò¹¡è͹¡ÒÃÃѺ»ÃÐÒ¹
ÂÒ
¨Ò¡¹Ñé¹µÃǨÊÒµÒØ¡à´×͹
àÁ×èͼÙé»èÇÂÁÒµÃǨ
µÔ´µÒÁ
áÅÐËÂØ´ÂÒѹÕÕèÁÕ¤ÇÒÁ¼Ô´»¡µÔ¢Í§ÊÒµÒ
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
à¾ÃÒÐÍÒ¨ÊÙàÊÕ¡ÒÃÓ§Ò¹¢Í§ÊÒµÒẺ¶ÒÇÃä´é
¼Å¢éÒ§à¤Õ§Í×è
¹
àªè
¹
¼×è
¹
»ÅÒ»ÃÐÊÒÍÑ¡àʺ
ä«â¤Å«ÕÃÕ¹ (cycloserine)
ä«â¤Å«ÕÃÕ¹ (cycloserine) à»ç¹ÂÒÍѹ´ÑºÃͧ
㹡ÒÃÃÑ¡ÉÒàª×éÍÇѳâä´×éÍÂÒ
ÍÒ¨ãªéªÑèǤÃÒÇÃèÇÁ¡Ñºã¹
¡Ã³Õ¼Ùé»èÇÂà¡Ô´µÑºÍÑ¡àʺ
ÂѺÂÑ駡ÒÃÊÃéÒ§à»çºµÔâ´ä¡Å
᤹ (peptidoglycan) ¢¹Ò´ÂÒã¹¼ÙéãËè 10-15
ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¢¹Ò´ÊÙ§ÊØ
´
1,000 ÁÔÅÅÔ¡ÃÑÁµèÍÇÑ
¹
â´Â»¡µÔãªé¢¹Ò´ 500-750
ÁÔÅÅÔ¡ÃÑÁµèÍÇÑ
¹
áºè§ãËéÇѹÅÐ 2 ¤ÃÑé
§
äÁè¤ÇÃãªéÂÒã¹
ËÔ§µÑ駤ÃÃÀìËÃ×ÍäµÇÒÂÕèÁÕ¤èÒ¡ÒáӨѴ¤ÃÕÍеԹÕ
¹
¹éÍÂ
¡ÇèÒ 50 ÁÔÅÅÔÅԵõè͹ÒÕÃÇÁÑé§à¾ÔèÁ¡Òêѡä´éã¹¼Ùé
»èÇÂÕèÁյѺÍÑ¡àʺ¨Ò¡ÊØÃÒ
¼Å¢éÒ§à¤Õ§ҧÃкº»ÃÐÊÒ
¨Ò¡ÂÒä«â¤«ÕÃÕ¹¾ºä´éµÑé§áµè»Ç´ÈÕÃÉÐ
ÍÒ¡ÒÃÒ§¨Ô
µ
¨¹¶Ö§ªÑ
¡
áµè¾º»ÅÒ»ÃÐÊÒÍÑ¡àʺ¹éÍÂÁÒ¡
â´Â
ÃÒ§ҹ¨Ò¡ Murray31 ¾ºÇèÒËÒ¡ÃѺ»ÃÐÒ¹ÂÒ 500
ÁÔÅÅÔ¡ÃÑ
Á
ÇѹÅÐ 2 ¤ÃÑé
§
¾ºÍÒ¡Òêѡä´é¶Ö§ 16% áµè
¶éÒÃѺ»ÃÐÒ¹ÂÒàËÅ×Í 500 ÁÔÅÅÔ¡ÃÑ
Á
ÇѹÅФÃÑé
§
¾ºÍÒ¡Òêѡà¾Õ§ÃéÍÂÅÐ 3 ÍÒ¨ãËéä¾ÃÔ´Í¡«Ô
¹
(pyridoxine) ÇѹÅÐ 100-200 ÁÔÅÅÔ¡ÃÑÁ»éͧ¡Ñ¹¡ÒÃ
à¡Ô´¼Å¢éÒ§à¤Õ§ҧ»ÃÐÊÒä´é¤ÇùѴµÃǨµÔ´µÒÁ
ÍÒ¡ÒÃÒ§¨ÔµáÅлÃÐÊÒÍÂèÒ§ÊÁèÓàÊÁÍ
ÇÑ´ÃдѺÂÒ
ã¹àÅ×Í´à¾×èÍ»ÃѺ¢¹Ò´ÂÒãËéàËÁÒÐÊÁ
àÍäâ͹ÒäÁ´ì (ethionamide)
àÍäâ͹ÒäÁ´ì (ethionamide) ÂÒÍѹ´ÑºÃͧ
ÊÓËÃѺàª×éÍÇѳâäÕè´×éÍÂÒÍÕ¡ª¹Ô´Ë¹Öè
§
ÂѺÂÑ駡ÒÃÊÃéÒ§
¡Ã´äÁâ¤ÅÔ¡ (mycolic acid) ¢¹Ò´ÂÒã¹¼ÙéãËè 1520
ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
â´Â»¡µÔãªé
¢¹Ò´ 500-750 ÁÔÅÅÔ¡ÃÑÁµèÍÇÑ
¹
áºè§ãËéÇѹÅÐ 1-2
¤ÃÑé
§
â´ÂãËé¡è͹¹Í¹ËÃ×Í¡è͹ÍÒËÒÃÁ×éÍËÅÑ
¡
à¹×èͧ¨Ò¡
¼Å¢éÒ§à¤Õ§ÊèǹãËèà¡ÕèÂǡѺÃкºÒ§à´Ô¹ÍÒËÒÃ
ÓãËé
àÊÕ¡ÒÃÃѺÃÙéÃÊ
¤Å×è¹äÊéÍÒà¨Õ¹
àº×èÍÍÒËÒÃ
»Ç´éͧ
ÍÒ¨¾ºµÑºÍÑ¡àʺä´éÃéÍÂÅÐ 2 à¾ÃÒÐâ¤Ã§ÊÃéÒ§¤ÅéÒÂ
äÍâ«ä¹ÍÐÊÔ
´
´Ñ§¹Ñ鹤ÇÃÃÐÇѧ¡ÒÃãªéÂÒã¹¼ÙéÕèÁÕâäµÑ
º
ÍÂÙèà´Ô
Á
áÅÐËÁÑè¹µÔ´µÒÁ¡ÒÃÓ§Ò¹¢Í§µÑºÍÂèÒ§ÊÁè
Ó
àÊÁÍ
¼Å¢éÒ§à¤Õ§ҧÃкºµèÍÁäÃéè
Í
àªè
¹
àµéÒ¹Áâµ
¢Öé
¹
¼ÁÃèǧ
µèÍÁ¸ÑÂÃÍ´ìÓ§Ò¹µè
Ó
ÊÙàÊÕ¤ÇÒÁµéͧ
¡ÒÃÒ§à¾È
ÍÒ¨¾º»ÑËÒ¡ÒûÃѺÃдѺ¹éÓµÒÅã¹¼Ùé»èÇÂ
àºÒËÇÒ¹ä´é¹Í¡¨Ò¡¹ÕéÂѧÁÕÃÒ§ҹ¾º»ÅÒ»ÃÐÊÒ
ÍÑ¡àʺ
»ÃÐÊÒµÒÍÑ¡àʺ
ÇÔµ¡¡Ñ§ÇÅ
«ÖÁàÈÃé
Ò
áÅÐ
ÍÒ¡ÒÃÒ§¨Ôµä´é»ÃÐÁÒ³ÃéÍÂÅÐ 1-2
äÁè¤ÇÃãªéÂÒ¹Õéã¹ËÔ§µÑ駤ÃÃÀìà¹×èͧ¨Ò¡ÂÒ¼èҹá
ä´éÊèǹ¼Ùé»èÇÂäµÇÒÂÕèÁÕ¤èÒ¡ÒáӨѴ¤ÃÕÍеԹÕ
¹
¹éÍÂ
¡ÇèÒ 30 ÁÔÅÅÔÅԵõè͹ÒÕ¤ÇÃÅ´¢¹Ò´ÂÒàËÅ×Í 250500
ÁÔÅÅÔ¡ÃÑÁµèÍÇÑ
¹
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
ÊàµÃçºâµäÁ«Ô¹ (streptomycin)
Í͡ĸìÔâ´ÂÂѺÂÑ駡ÒÃÊÃéÒ§â»ÃµÕ¹¢Í§àª×é
Í
Çѳâä
¢¹Ò´ÂÒã¹¼ÙéãËè 15 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1
¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ÍÒ¨ãËé 10 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1
¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¶éÒÍÒÂØÁÒ¡¡ÇèÒ 59 »ÕËÃ×ͼÙé»èÇÂäµÇÒÂ
â´ÂÊèǹãËèãËéÂÒ 5-7 ÇѹµèÍÊÑ»´ÒË
ì㹪èǧ 2-4
à´×͹áá
¨Ò¡¹Ñ鹨֧ŴàËÅ×Í 2-3 ÇѹµèÍÊÑ»´ÒË
ì
¼Å¢éÒ§à¤Õ§ÕèÊÓ¤ÑÕèÊØ
´
¤×
Í
¾ÔɵèÍÃкºËÙÑé
§
¡ÒÃä´éÂÔ¹áÅСÒÃçµÑ
Ç
¾º»Ñ¨¨ÑÂàÊÕè§à¾ÔèÁ¢Öé¹ã¹¼ÙéÊÙ
§
ÍÒÂØËÔ§µÑ駤ÃÃÀ
ì¼ÙéãªéÂҢѺ»ÑÊÊÒÇÐÃèÇÁ´éÇÂ
¼ÙéãªéÂÒ
streptomycin ¢¹Ò´ÊÙ
§
ËÃ×Í¢¹Ò´ÂÒÊÐÊÁÁÒ¡¡Çè
Ò
100-120 ¡ÃÑ
Á
¼Å¢éÒ§à¤Õ§Í×è
¹
ä´éá¡è¾ÔɵèÍÃкº
»ÃÐÊÒ
¾ºÁÕÍÒ¡ÒêÒÃͺ»Ò¡ä´éѹÕËÅѧ©Õ´ÂÒ
¾Ô
É
µèÍÃкºäµâ´Â¾º¹éÍ¡ÇèÒÂÒµÑÇÍ×è¹ (amikacin,
kanamycin, or capreomycin) ÁÕ¡ÒÃÈÖ¡ÉÒã¹»Õ¾.È.
2490 32¾º¼Ùé»èÇÂäµÇÒÂÕèµéͧËÂØ´ÂÒ»ÃÐÁÒ³ÃéÍÂÅÐ 2
´Ñ§¹Ñ鹤ÇõÃǨ¡ÒÃÓ§Ò¹¢Í§äµ
¡ÒÃä´éÂÔ¹àÊÕ§
ÃÇÁ
¶Ö§¡ÒÃçµÑÇäÇéà»ç¹¾×é¹°Ò¹¡è͹àÃÔèÁÂÒÊàµÃçºâµäÁ«Ô
¹
ÍÐÁÔ¤Ò«Ô¹áÅФҹÒäÁ«Ô¹ (amikacin and
kanamycin)
ÂÒÍѹ´ÑºÃͧª¹Ô´©Õ´ÍÕ¡ª¹Ô´Ë¹Öè§ã¹¡ÒÃÃÑ¡ÉÒ
Çѳâä´×éÍÂÒ
«Öè§ÂÒÊͧª¹Ô´¹ÕéÊÒÁÒö´×éÍ¢éÒÁ¡Ñ¹ä´éÊèǹ
ÊÒ¾ѹ¸ìØÕè´×éÍ streptomycin ÂѧµÍºÊ¹Í§µèÍÂÒÊͧ
ª¹Ô´¹Õéä´é¢¹Ò´áÅÐáÅмŢéÒ§à¤Õ§µèÍÃкºËÙàËÁ×͹
ÂÒ streptomycin áµè¡èÍãËéà¡Ô´¼Å¡Ãк´éÒ¹¡ÒÃç
µÑǹéÍ¡Çè
Ò
¨Ò¡ÃÒ§ҹ¡ÒÃÈÖ¡ÉҢͧ Black áÅÐ
¤³Ð33 ¾ºÇèÒÂÒ amikacin ¡èÍãËéà¡Ô´¡ÒÃÊÙàÊÕ¡ÒÃ
ä´éÂÔ¹àÊÕ§¤ÇÒÁ¶ÕèÊÙ§ä´é¶Ö§ÃéÍÂÅÐ 24 áÅоºÍѵÃÒ¡ÒÃ
à¡Ô´ÊÙ§¢Öé¹ã¹ÃÒÂÕèä´éÂÒ¢¹Ò´ÊÙ§áÅÐËÃ×ÍÃÐÂÐàÇÅÒ¹Ò¹
¢Öé
¹
ÂÒ amikacin áÅÐ kanamycin ÓãËéà¡Ô
´
¼ÅàÊÕµèÍäµÁÒ¡¡ÇèÒÂÒ streptomycin â´Â੾ÒÐÍÂèÒ§
ÂÔè§ÃÒÂÕèÁÕ¤èÒ¤ÃÕÍеԹչÊÙ§ÍÂÙè¡è͹
ãªéÂÒ¢¹Ò´ÊÙ
§
áÅÐ
ä´éÃѺÂÒÍ×è¹ÕèÁÕ¼ÅàÊÕµèÍäµÃèÇÁ´éÇÂ
à¹×èͧ¨Ò¡ÂҢѺÍÍ¡
񤊵
¨Ö§¤ÇÃãªéÂÒ´éǤÇÒÁÃÐÁÑ´ÃÐÇÑ
§
ÃÇÁÑ駵ÃǨ
¡ÒÃÓ§Ò¹¢Í§äµà»ç¹ÃÐÂÐæ
¹Í¡¨Ò¡¹ÕéÂѧÁռŵèÍäµ
¢Í§Òá㹤ÃÃÀìáÅСèÍãËéà¡Ô´ËÙ¾Ô¡ÒÃáµè¡Óà¹Ô
´
´Ñ
§
¹Ñé¹äÁè¤ÇÃãªéÂÒÊͧª¹Ô´¹Õéã¹ËÔ§µÑ駤ÃÃÀ
ì
¤Ò»ÃÕâÍäÁ«Ô¹ (capreomycin)
¤Ò»ÃÕâÍäÁ«Ô¹ (capreomycin) ÂÒ©Õ´ãªéä´éÑé
§
à¢éÒ¡ÅéÒÁà¹×éÍáÅÐà¢éÒËÅÍ´àÅ×Í´´Ó
ãªéÃÑ¡ÉÒÇѳâä´×é
Í
ÂÒ
¢¹Ò´ÂÒã¹¼ÙéãËè 15 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1
¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ÊèǹãËèãËéÂÒ 5-7 ÇѹµèÍÊÑ»´ÒËìã¹
ªèǧáá
áÅÐÅ´àËÅ×Í 2-3 ÇѹµèÍÊÑ»´ÒË
ìã¹ 2-3
à´×͹¶Ñ´ÁÒËÃ×ÍËÅѧ¨Ò¡¼Åà¾ÒÐàª×éÍ¡ÅѺÁÒà»ç¹»¡µÔ
ÍÂèÒ§äáç´Õ¤ÇÃÅ´¢¹Ò´ÂÒã¹¼ÙéÊÙ§ÍÒÂؼÙéÁÕÀÒÇÐäµÓ§Ò¹
º¡¾Ãèͧ
ÀÒÇÐâ»áµÊà«ÕÂÁËÃ×ÍáÁ¡¹Õà«ÕÂÁµè
Ó
áÅÐ
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
äÁè¤ÇÃãªéÂÒã¹ËÔ§µÑ駤ÃÃÀì¹Í¡¨Ò¡¹ÕéÂѧú¡Ç¹¡ÒÃç
µÑ
Ç
ÓãËéä´éÂÔ¹àÊÕ§¼Ô´»¡µÔã¹ËÙáÅÐËÙ˹ǡä´é¡è͹
¡ÒÃãªéÂÒ¤ÇõÃǨ¡ÒÃÓ§Ò¹¢Í§äµ
ÃдѺà¡Å×ÍáÃèâ»
áµÊà«ÕÂÁáÅÐáÁ¡¹Õà«ÕÂÁ
äÇéà»ç¹¾×é¹°Ò¹áÅеÃǨ
ÃÐËÇèÒ§¡ÒÃãªéÂÒà»ç¹ÃÐÂÐæ
´éÇÂ
¾ÒÃÒÍÐÁÔ⹫ÒÅÔÊÔÅÔ
¡
áÍÊÔ
´
(para-aminosalicylic
acid)
¾ÒÃÒÍÐÁÔ⹫ÒÅÔÊÔÅÔ
¡
áÍÊÔ
´
(paraaminosalicylic
acid) ¢Ñ´¢ÇÒ§¡Ãкǹ¡ÒÃàÁµÒâºÅÔ
ÊÁ¢Í§¡Ã´â¿ÅÔ¡áÅÐàËÅç
¡
ª¹Ô´ÃѺ»ÃÐÒ¹¢¹Ò´ 812
¡ÃÑ
Á
áºè§ãËé 2-3 ¤ÃÑ駵èÍÇÑ
¹
ÁÕ¡ÒÃÃǺÃÇÁ34¼Ùé»èÇÂ
Çѳâä 7,492 ÃÒÂ
¾ºÇèÒ 38 ÃÒ (ÃéÍÂÅÐ 0.5) à¡Ô
´
µÑºÍÑ¡àʺ
¼Å¢éÒ§à¤Õ§Í×è
¹
ä´éá¡è¡Òôٴ«ÖÁä¢Áѹ¼Ô
´
»¡µÔÃдѺâ¿àŵã¹àÅ×Í´µè
Ó
µèÍÁ¸ÑÂÃÍ´ìÓ§Ò¹µè
Ó
¡ÒÃá¢ç§µÑǢͧàÅ×Í´¼Ô´»¡µÔ´Ñ§¹Ñ鹤ÇõÃǨàÅ×Í´Ò§
Ëéͧ»‾ԺѵԡÒÃÍÂèÒ§ÊÁèÓàÊÁÍØ¡ 1-3 à´×͹
¿ÅÙÍÍâäÇÔâ¹âŹ (fluoroquinolones)
¿ÅÙÍÍâäÇÔâ¹âŹ (fluoroquinolones) ä´éá¡è
ÅÕâÇ¿ÅÍ¡«Ò«Ô¹ (levofloxacin) ÁÍ¡ÊÔ¿ÅÍ¡«Ò«Ô
¹
(moxifloxacin, MXF) áÅСҵԿÅÍ¡«Ò«Ô
¹
(gatifloxacin) ¨Ò¡¡ÒôÅͧã¹Ë¹Ù35 ¾ºÇèÒàÁ×èÍãËé
ÂÒÁÍ¡ÊÔ¿ÅÍ¡«Ò«Ô¹ÃèÇÁ¡ÑºäÃá¿Á¾Ô«Ô¹áÅÐä¾ÃÒ«Ô¹Ò
äÁ´ì (MXF-RIF-PZA) ÁÕ»ÃÐÊÔ¸ÔÀҾ㹡Òæè
Ò
àª×éÍÇѳâä´Õ¡ÇèÒÂÒäÍâ«ä¹ÍÐÊÔ
´
äÃá¿Á¾Ô«Ô¹áÅÐä¾
ÃÒ«Ô¹ÒäÁ´ì (INH-RIF-PZA) ÂÒ㹡ÅØèÁ¹ÕéÍ͡ĸ
ìÔ
ÂѺÂÑ駡ÒÃÊÃéÒ§¡Ã´´ÕÍÍ¡«ÕäÃ⺹ÔǤÅÕÍÔ¤ (DNA) ¶Ö
§
áÁéäÁèä´éÃѺ¡ÒÃÂÍÁÃѺ¨Ò¡Í§¤ì¡ÒÃÍÒËÒÃáÅÐÂÒ
áµè¶Ù
¡
¹ÓÁÒãªéã¹ÃÒÂÕè´×éÍÂÒËÃ×͹¼Å¢éÒ§à¤Õ§¢Í§ÂÒËÅÑ¡äÁè
ä´é«Öè§ã¹Í¹Ò¤µÂÒ¡ÅØèÁ¿ÅÙÍÍâäÇÔâ¹âŹ¹ÕéÍÒ¨¶Ù¡¹ÓÁÒ
ãªéà»ç¹ÂÒËÅѡ㹡ÒÃÃÑ¡ÉÒÇѳâäÑ駴×éÍÂÒáÅÐäÁè´×éÍÂÒ
ä´é¢¹Ò´¢Í§ÂÒÅÕâÇ¿ÅÍ¡«Ò«Ô¹ 500-1,000 ÁÔÅÅÔ¡ÃÑ
Á
µèÍÇÑ
¹
¢¹Ò´¢Í§ÂÒÁÍ¡ÊÔ¿ÅÍ¡«Ò«Ô¹ 400 ÁÔÅÅÔ¡ÃÑ
Á
µèÍÇÑ
¹
ÂÒ¡ÅØèÁ¹Õé¼èÒ¹à¢éÒÃкº»ÃÐÊÒÊèǹ¡ÅÒ§äÁè´Õ¹Ñ
¡
»ÃÐÁÒ³ÃéÍÂÅÐ 16-20 ¢Í§ÃдѺÂÒ㹡ÃÐáÊàÅ×Í´
ÃÇÁÑé§Âѧ´×éÍÂÒä´éÃÇ´àÃç
Ç
¨Ö§¤ÇÃàÅ×Í¡ãªéÂÒãËéàËÁÒÐ
ÊÁ
¼Å¢éÒ§à¤Õ§ÃкºÒ§à´Ô¹ÍÒËÒà (ÃéÍÂÅÐ 0.51.8)
ä´éá¡è¤Å×è¹äÊééͧÍ×
´
Ãкº»ÃÐÊÒ (ÃéÍÂÅÐ
0.5) ä´éá¡èàÇÕ¹ÈÕÃÉÐ
»Ç´ÈÕÃÉÐ
¹Í¹äÁèËÅÑ
º
Ãкº
¼ÔÇ˹ѧ (ÃéÍÂÅÐ 0.2-0.4) ä´éá¡è¼×è
¹
¤Ñ
¹
¼×è¹á¾éáʧ
ÂÒÅ´¡Ã´áÅÐÂÒÕè
ÁÕ
Êèǹ»ÃСͺ¢Í§
»ÃШغǡú¡Ç¹¡Òôٴ«ÖÁÂÒ¡ÅØèÁ¿ÅÙÍÍâäÇÔâ¹âŹ
¤ÇÃÃѺ»ÃÐÒ¹ÂÒËèÒ§¨Ò¡ÂÒàËÅèÒ¹ÕéÍÂèÒ§¹éÍÂÊͧªÑèÇâÁ§
ÂÒ¡ÅØèÁ¹Õé¶Ù¡¢ÑºÍ͡ҧ䵻ÃÐÁÒ³ÃéÍÂÅÐ 80 ¨Ö§¤ÇÃ
»ÃѺ¢¹Ò´ÂÒàÁ×èͼÙé»èÇÂÁÕ¤èÒ¡ÒáӨѴ¤ÃÕÍеԹÕ
¹
¹éÍ¡Çè
Ò
50 ÁÔÅÅÔÅԵõè͹Òչ͡¨Ò¡¹ÕéÂÒäÁè¶Ù¡¡Ó¨Ñ´â´Â¡ÒÃ
¿Í¡äµ´Ñ§¹Ñé¹äÁèµéͧà¾ÔèÁ¢¹Ò´ÂÒÍÕ¡ËÅѧÅéÒ§äµ
ÂÒ¡ÅØèÁÍÍ¡«Òâ«ÅÔ´Ôâ¹¹ (oxazolidinones)
ÂÒ»‾ÔªÕǹСÅØèÁãËÁèä´éÃѺ¡ÒÃÂÍÁÃѺâ´Â
ͧ¤ì¡ÒÃÍÒËÒÃáÅÐÂҢͧÊËÃÑ°ÍàÁÃÔ¡Ò
㹡ÒÃÃÑ¡ÉÒ
ẤÕàÃÕÂá¡ÃÁºÇ¡´×éÍÂÒ
Í͡ĸìÔâ´ÂÂѺÂÑ駢Ñ鹵͹
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
áá¢Í§¡ÒÃÊÃéÒ§â»ÃµÕ¹â´Â¡ÒèѺÊèǹ¢Í§äÃâºâ«Á
ª¹Ô´ 50S (ribosomel 50S subunits) ÕèÊèǹãËèÍÂÙè
ÀÒÂã¹â´àÁ¹ 5 ¢Í§äÃ⺹ÔǤÅÕÍÔ¤ª¹Ô´ 23S (domain
V of the 23S rRNA) ¹Í¡¨Ò¡¹ÕéÂѧÁÕĸìÔµéÒ¹àª×é
Í
Çѳâäã¹Ë¹ÙÍÂèÒ§äáç´ÕÂѧäÁèÁÕÃÒ§ҹ¡ÒÃãªéÂÒ¹Õé㹤¹
ÂÒ¡ÅØèÁÍÐâ«Å (azole drugs)
Miconazole
¡ÅØèÁÂÒÃÑ¡ÉÒàª×éÍÃÒÕèÊÒÁÒöÂѺÂÑ駡ÒÃàµÔºâµ
¢Í§àª×éÍÇѳâää´éàªè
¹
ÂÒäÁ⤹Òâ«Å (miconazole)
ÂÒâ¤ÅäµÃÁÒâ«Å (clotrimizole) ÂÒÍ͡ĸìÔÕèÊèǹ
¢Í§â¤ÃâÁâ«Á¢Í§àª×éÍÇѳâä
ÕèÁÕÊèǹ»ÃСͺҧà¤ÁÕ
¤ÅéÒÂä«âµâ¤ÃÁ¾Õ 450 (cytochrome P 450
homologs) Ñé§ã¹ÃÐÂСÓÅѧáºè§µÑÇáÅÐÃÐÂÐÍÂÙè¹Ôè
§
¹Óä»ÊÙè¡ÒÃÈÖ¡ÉÒ¤ÇÒÁÊÑÁ¾Ñ¹¸ìÃÐËÇèÒ§ä«âµâ¤ÃÁ¾Õ 450
áÅФÇÒÁäǢͧàª×é͵èÍÂÒÍÐâ«Å
«Ö觤§µéͧÃÍ¡ÒÃ
ÈÖ¡ÉÒãËÁèæµèÍä»ã¹Í¹Ò¤µ
ËÅÑ¡¡ÒÃÃÑ¡ÉÒÇѳâä
¨Ø´»ÃÐʧ¤ìËÅѡ㹡ÒÃÃÑ¡ÉÒÇѳâä
¤×
Í
¡Ó¨Ñ
´
àª×éÍÇѳâäÍÂèÒ§ÃÇ´àÃç
Ç
Å´¡ÒÃà¡Ô´¡Òô×éÍÂÒ
áÅÐ
»éͧ¡Ñ¹¡ÒáÅѺà»ç¹«éӢͧâäà¾×èÍãËéºÃÃÅØÇѵ¶Ø»ÃÐʧ¤
ì
¨Ö§ÁÕ¡ÒÃãªéÂÒËÅÒª¹Ô´à»ç¹ÃÐÂÐàÇÅÒ¹Ò¹
ËÅÒÂÄÉ®Õ
¡ÅèÒǶ֧¡ÒáÅÒ¾ѹ¸ìآͧàª×éÍ (mutation) ÕèÓãËé
à¡Ô´¡Òô×éÍÂÒ
¾ºÇèÒÁÕ¡ÒáÅÒ¾ѹ¸ìصÒÁ¸ÃÃÁªÒµÔ¢Í§
àª×éÍÇѳâäµèÍÂÒ isoniazid áÅÐ streptomycin
»ÃÐÁÒ³ 1 ã¹ 106 µèÍÂÒäÃá¿Á»Ô¹»ÃÐÁÒ³ 1 ã¹ 108
áÅеèÍÂÒÍÕáÁºÙÍÅ»ÃÐÁÒ³ 1 ã¹ 105 ´Ñ§¹Ñé¹ÊÓËÃÑ
º
¡ÒáÅÒ¾ѹ¸ìصèÍÂÒäÍâ«ä¹ÍÐÊÔ´áÅÐäÃá¿Á»Ô¹¾ºã¹
ÍѵÃÒ 1 ã¹ 1014 ¨Ö§à»ç¹¡ÒÃÂÒ¡Õè¨Ð´×éÍÂÒ 2 ª¹Ô´¹Õé
¾ÃéÍÁ¡Ñ
¹
´Ñ§¹Ñé¹ËÅÒ¡ÒÃÈÖ¡ÉÒáÊ´§ãËéàËç¹ÇèÒ¡ÒÃãËé
ÂÒËÅÒª¹Ô´ÃèÇÁ¡Ñ
¹
»éͧ¡Ñ¹¡ÒÃà¡Ô´àª×éÍ´×éÍÂÒä´éÁÒ¡¡Çè
Ò
¡ÒÃãËéÂÒà¾Õ§ª¹Ô´à´ÕÂÇ
¡ÒÃÃÑ¡ÉÒ㹻Ѩ¨ØºÑ¹¨Ö§á¹Ð¹ÓãËé
ãªéÂÒäÍâ«ä¹ÍÐÊÔ´áÅÐäÃá¿Á»Ô¹ÃèÇÁ¡ÑºÂÒÍ×è
¹
àªè
¹
ÂÒ
ÍÕáÁºÙÍÅáÅÐÊàµÃçºâµäÁ«Ô
¹
¼Ùé»èÇÂÊèǹãËèµÍºÊ¹Í§µèÍ¡ÒÃÃÑ¡ÉÒà»ç¹ÍÂèÒ§
´Õ¾ºÇèÒÁÒ¡¡ÇèÒÃéÍÂÅÐ 80 µÃǨàÊÁËÐäÁ辺àª×é
Í
ÀÒÂ
ËÅѧ¡ÒÃÃѺ»ÃÐÒ¹ÂÒ»ÃÐÁÒ³Êͧà´×͹
Êèǹ¼Ùé»èÇÂÕè
àËÅ×ÍÁÕ¡ÒáÅѺà»ç¹«éӢͧâäáÅÐäÁèµÍºÊ¹Í§µèÍ¡ÒÃ
ÃÑ¡ÉÒâ´Â੾ÒÐÍÂèÒ§ÂÔè§ÃÒÂÕèÃѺ»ÃÐÒ¹ÂÒäÁè¹Ò¹¾Í
¼ÙéÕèʧÊÑÂÇèÒà»ç¹Çѳâä
¤ÇÃä´éÃѺ¡ÒÃãªéÇÔ
¸Õ
Áҵðҹ㹡ÒÃà¡ç
º
¡ÒùÓÊè
§
¡ÒÃà¾ÒÐàª×éÍáÅÐÂ×¹ÂÑ
¹
¼Å¡ÒÃà¾ÒÐàª×éͨҡÊÔè§Ê觵ÃǨ
ÃÇÁ¶Ö§µÃǨ¤ÇÒÁäÇ
¢Í§àª×éÍÇѳâäµèÍÂÒ»‾ÔªÕǹÐ
â´Âà¡çºàÊÁËÐÊ觵ÃǨ
ÍÂèÒ§¹éÍÂÊÒÁ¤ÃÑé
§
ËèÒ§¡Ñ¹ 8-24 ªÑèÇâÁ§
¶éÒäÁèÊÒÁÒö
à¡çºàÊÁËÐä´éãËé¡ÃеØé¹ãËéäÍ´éǹéÓà¡Å×Íà¢éÁ¢é¹ËÃ×
Í
Êèͧ¡ÅéͧËÅÍ´ÅÁ
áÅÐ᡼ÙéÕèʧÊÑÂËÃ×ÍÂ×¹ÂѹÇèÒà»ç
¹
Çѳâä
à¾×èÍÅ´¡ÒÃá¾Ãè¡ÃШÒÂàª×é
Í
̂禅
§
ÃÒ§ҹ¼Ùé
ÕèµÔ´àª×é͵èÍ˹èǧҹÊØ¢ÀÒ¾ã¹áµèÅо×é¹Õèà¾×èÍ¡ÒÃ
ÃÑ¡ÉÒÍÂèÒ§µèÍà¹×èͧËÅѧ¼Ùé»èÇÂÍÍ¡¨Ò¡âç¾ÂÒºÒÅ
Ñé
§
ÂѧÊÒÁÒöËÒ¼ÙéµÔ´àª×éÍÃÒÂÍ×è¹ÕèÊÑÁ¼ÑʡѺ¼Ùé»èÇ (µÒÃÒ§
Õè 3)
¡Ã³ÕÕè¼ÅàÊÁÕÂÃìËÃ×ͼÅà¾ÒÐàª×éÍà»ç¹»¡µÔËÃ×
Í
ÃÒÂÕèµÔ´àª×éÍäÇÃÑÊàͪäÍÇÕµÔ´ÂÒàʾµÔ´ª¹Ô´©Õ´à¢é
Ò
ËÅÍ´àÅ×Í´´Ó
ÊÑÁ¼ÑÊã¡ÅéªÔ´¼Ùé»èÇÂÇѳâä
ÍÒ¨ãªéÇÔ
¸Õ
´Êͺҧ¼ÔÇ˹ѧâ´Â¹Óâ»ÃµÕ¹ÁÒÊ¡Ñ´ãËéºÃÔÊظìÔàÃÕ¡
¡ÒôÊͺÙàºÍÃì¤ÙÅÔ¹ (PPD-tuberculin skin test)
â´Â¡ÒÃãªéÇÔ¸Õ Mantoux ÁÒªèÇÂ㹡ÒûÃСͺ¡ÒÃ
ÇÔ¹Ô¨©Ñ
Â
«Öè§ÇÔ¸Õ¹ÕéÓ§èÒÂ
¼Å¢éÒ§à¤Õ§¹éÍÂ
ÍèÒ¹¼ÅËÅÑ
§
¡ÒôÊͺÕè 48-72 ªÑèÇâÁ§
â´Â¶×ÍÇèÒà»ç¹ºÇ¡
ã¹
¡Ã³Õ´Ñ§µèÍ仹Õé
-¢¹Ò´ÁÒ¡¡ÇèÒËÃ×ÍàèҡѺ 5 ÁÔÅÅÔàÁµÃ
ã¹
ÃÒÂÕèÊÑÁ¼ÑÊã¡ÅéªÔ´¼Ùé»èÇÂÇѳâä
µÔ´àª×éÍäÇÃÑÊàͪäÍÇÕ
ÀÒÇÐÀÙÁÔ¤ØéÁ¡Ñ¹µè
Ó
ËÃ×ÍÀÒ¾ÃѧÊÕÇÔÂҢͧ»Í´ºè§ÇèÒà¤Â
µÔ´àª×éÍÇѳâäÁÒ¡è͹
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
-¢¹Ò´ÁÒ¡¡ÇèÒËÃ×ÍàèҡѺ 10 ÁÔÅÅÔàÁµÃ
ã¹
ÃÒÂÕèà´Ô¹Ò§ÁÒ¨Ò¡áËÅè§ÕèÁÕ¤ÇÒÁªØ¡¢Í§Çѳâä
µÔ
´
ÂÒàʾµÔ´ª¹Ô´©Õ´à¢éÒËÅÍ´àÅ×Í´´Ó
ËÃ×Íã¹à´ç¡ÍÒÂعéÍÂ
¡ÇèÒ 4 »Õ
-¢¹Ò´ÁÒ¡¡ÇèÒËÃ×ÍàèҡѺ 15 ÁÔÅÅÔàÁµÃ
ã¹
ÃÒÂÕèäÁèà¤ÂÊÑÁ¼ÑÊáÅÐäÁèÁջѨ¨ÑÂàÊÕ觵èÍ¡ÒÃà¡Ô´âä
¼ÙéÕèµÔ´àª×éÍÇѳâä¤ÇÃä´éÃѺ¡ÒõÃǨËÒàª×éÍäÇÃÑ
Ê
àͪäÍÇÕÀÒÂã¹ 2 à´×͹
ËÅѧ¡ÒÃÇÔ¹Ô¨©ÑÂÇèÒà»ç¹Çѳâä
à¾×èÍ»ÃÐ⪹ì㹡ÒÃá¹Ð¹Ó¼Ùé»èÇÂ
¡ÒÃËÒâäµÔ´àª×éÍ©ÇÂ
âÍ¡ÒÊÍ×è¹æ
áÅÐàÅ×Í¡ÂÒµéÒ¹äÇÃÑÊàÍ´Ê
ìâ´ÂÊÒÁÒö
ÃÑ¡ÉÒ´éÇÂÊÙµÃÂÒÁҵðҹä´éÁÕà¾Õ§ºÒ§ÃÒÂàèÒ¹Ñé¹ÕèÍÒ¨
µéͧÃÑ¡ÉÒ´éÇÂÃÐÂÐàÇÅÒÕè¹Ò¹¢Öé
¹
ÃÒ§ҹ¨Ò¡ÊËÃÑ
°
ÍàÁÃÔ¡Òã¹»Õ¾.È. 2536-2537 ¾ºÇèÒÃéÍÂÅÐ 14 ¢Í§¼Ùé
»èÇÂÇѳâäµÃǨ¾ºàª×éÍàͪäÍÇÕáÅкҧ¾×é¹Õè
¾ºâäàÍ´ÊìÃèÇÁ¡ÑºÇѳâä¶Ö§ÃéÍÂÅÐ 58
µÒÃÒ§Õè 3. áÊ´§¤Óá¹Ð¹ÓÊÓËÃѺ¡ÒôÙáÅÃÑ¡ÉÒÇѳâä㹻ÃÐàÈÊËÃÑ°ÍàÁÃÔ¡Ò
INH : isoniazid, RIF : rifampicin, PZA : pyrazinamide, EMB : ethambutol, SM : st
reptomycin, TB :
tuberculosis, CDC : Center for Diseases Control and Prevention
-Obtain bacteriologic confirmation and susceptibility testing for patients with
TB or
suspected of having TB
-Place persons with suspected or confirmed smear-positive pulmonary or laryngeal
TB in
respiratory isolation until noninfectious
-Begin treatment of patients with confirmed or suspected TB disease with 1 of th
e
following drug combinations, depending on local resistance patterns: INH, RIF, P
ZA, or
INH, RIF, PZA, EMB, or INH, RIF, PZA, SM
-Report each case of TB promptly to the local public health department
-Perform HIV testing for all patients with TB
-Treat patients with TB caused by a susceptible organism for 6 months, using an
ATS/
CDC-approved regimen
-Reevaluate patients with TB who are smear positive at 3 months for possible non
adherence
or infection with drug-resistant bacilli
-Add >2 new antituberculosis agents when TB treatment failure is suspected
-Perform tuberculin skin testing on all patients with a history of >1 of the fol
lowing: HIV
infection, injection drug use, homelessness, incarceration, or contact with a pe
rson with
pulmonary TB
-Administer treatment for latent TB infection to all persons with latent TB infe
ction, unless
it can be documented that they received such treatment previously
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
¡ÒõѴÊÔ¹ã¨àÃÔèÁÂÒÃÑ¡ÉÒÇѳâä¤ÇÃãªé¢éÍÁÙÅ´éÒ¹
ÃкҴÇÔÂÒ
ÍÒ¡ÒÃÒ§¤ÅÔ¹Ô
¡
¼Å¡ÒõÃǨàÊÁËÐÍÂèÒ§
¹éÍÂÊÒÁ¤ÃÑé
§
áÅÐÀÒ¾Ò§ÃѧÊÕÇÔÂÒà»ç¹¾×é¹°Ò¹
ÍÂèÒ§
äáç´Õ¤ÇÃàÃÔèÁ¡ÒÃÃÑ¡ÉÒ´éÇÂÂÒÊÕ誹Ô
´
â´ÂäÁèµéͧÃÍ
¼Å¡ÒÃà¾ÒÐàª×éÍÇѳâäáÅСóÕÕè¼ÅàÊÁÕÂÃìà»ç¹»¡µÔáµè
ÍÒ¡ÒÃÒ§¤ÅÔ¹Ô¡à¢éÒä´é¡ÑºÇѳâä¡çµÒÁ
¡àÇ鹡óÕÍÂÙè
㹶Ôè¹Õè´×é͵èÍÂÒäÍâ«ä¹ÍÐÊÔ
´
¹éÍ¡ÇèÒÃéÍÂÅÐ 4
ÊÒÁÒöãªéÂÒ 3 ª¹Ô´ä´é
ÂÒÕè¶×ÍÇèÒà»ç¹Áҵðҹ㹡ÒÃÃÑ¡ÉÒà»ç¹Íѹ´Ñ
º
áá
¤×
Í
ÂÒäÍâ«ä¹ÍÐÊÔ
´
ÂÒäÃá¿Á»Ô
¹
ÂÒä¾ÃÒ«Ô
¹ÒäÁ´
ìáÅÐÂÒÍÕáÁºÙÍÅ
¨Ö§ÁÕ¡ÒÃáºè§ÃÐÂÐàÇÅÒ¡ÒÃ
ÃÑ¡ÉÒà»ç¹ 2 ªèǧ
¤×
Í
ÃÐÂÐà¢éÁ¢é¹ 2 à´×͹áá
(intensive phase) ãªéÂÒ 4 ª¹Ô´¢éÒ§µé
¹
áÅÐ 4 à´×͹
¶Ñ´ÁÒà»ç¹ÃÐÂеèÍà¹×èͧ (continuation or
maintenance phase) ãªéÂÒ 2 ª¹Ô
´
¤×
Í
ÂÒäÍâ«ä¹
ÍÐÊÔ
´
áÅÐäÃá¿Á»Ô
¹
¡ÒÃÃѺ»ÃÐÒ¹ÂÒà»ç¹àÇÅÒ 6 à´×͹ (26
ÊÑ»´ÒËì) à»ç¹ÁҵðҹÕèãªé¡Ñ¹ã¹»Ñ¨¨ØºÑ
¹
Ñé§ã¹à´ç¡áÅÐ
¼ÙéãËèÕè¼Åà¾ÒÐàª×éÍÇѳâäà»ç¹ºÇ¡
ÊÓËÃѺ㹼ÙéãËèáºè
§
à»ç¹ËÅÒÂÊٵà (µÒÃÒ§Õè 4-5) »ÃСͺ´éÇ INH,
RIF, PZA, áÅÐ EMB ÇѹÅФÃÑé§ã¹ 2 à´×͹áá
(ÊÙµÃÕè 1) ËÃ×ÍÇѹÅФÃÑé§ã¹ 2 ÊÑ»´ÒËìáá
µÒÁ´éÇÂ
2 ¤ÃÑ駵èÍÊÑ»´ÒË
ìã¹ 6 ÊÑ»´ÒËìµèÍÁÒ (ÊÙµÃÕè 2) ËÃ×
Í
3 ¤ÃÑ駵èÍÊÑ»´ÒËì (ÊÙµÃÕè 3) ÊÙµÃÂÒàËÅèÒ¹Õéä´éÃѺ¡ÒÃ
ʹѺʹعâ´Â¡ÒÃÈÖ¡ÉÒẺÂé͹ËÅѧ¨Ò¡ The British
Medical Research Council (BMRC) ¾º¡Òô×é
Í
ÂÒäÍâ«ä¹ÍÐÊÔ´áµèäÁè¤è;º¡ÒÃÃÑ¡ÉÒÅéÁàËÅÇËÃ×
Í
¡ÒáÅѺà»ç¹«é
Ó
¶éÒãªéÂÒÃèÇÁ¡Ñ¹Ñé§ 4 ª¹Ô´ã¹ÃÐÂÐ
à¢éÁ¢é
¹
¶éÒÊÒÁÒöµÃǨÂ×¹ÂѹÇèÒàª×éÍäǵèÍÂÒäÍâ«ä¹
ÍÐÊÔ´áÅÐäÃá¿Á¾Ô«Ô¹¨ÃÔ
§
ÍÒ¨äÁè¨Óà»ç¹µéͧãªéÂÒÍÕ
áÁºÙÍÅËÃ×ÍÊÒÁÒöËÂØ´ÂÒä´éѹÕËÅѧÃÒº¼Å¡ÒÃ
´Êͺ
ÍÂèÒ§äáç´Õ¤ÇÒÁà»ç¹¨ÃÔ§ÁÑ¡äÁèÃÒº¼Å¡ÒÃ
´Êͺ¡è͹ 4-8 ÊÑ»´ÒË
ì
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
µÒÃÒ§Õè 4. ÊÙµÃÂÒÃÑ¡ÉÒÇѳâä»Í´Õè¼Åà¾ÒÐàª×éÍà»ç¹ºÇ¡
1 : isoniazid, R : rifampicin, 2 : pyrazinamide, E : ethambutol, wk : week
Initial phase Continuation phase
Regimen Drugs Interval and dose Drugs Interval and dose
1 IRZE 7 days/wk for 56 doses
(8 weeks) or5 days/wk for40 doses
(8 weeks)
IR
IR
7 days/wk for 126 doses
(18 weeks) or
5 days/wk for 90 doses
(18 weeks)
Twice weekly for 36 doses
(18 weeks)
2 IRZE 7 days/wk for 14 doses
(2 weeks) then
twice weekly for 12 doses
(6 weeks) or
5 days/wk for 10 doses
(2 weeks) then
twice weekly for 12 doses
(6weeks)
IR Twice weekly for 36 doses
(18 weeks)
3 IRZE 3 times/wk for 24 doses
(8 weeks)
IR 3 times/wk for 54 doses
(18 weeks)
4 IRE 7 days/wk for 56 doses
(8 weeks) or
5 days/wk for 40 doses
(8 weeks)
IR
IR
7 days/wk for 217 doses
(31 weeks) or
5 days per week for 155 doses
(31 weeks)
Twice weekly for 62 doses
(31 weeks)
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
µÒÃÒ§Õè 5. áÊ´§¢¹Ò´ÂÒÕèãªéã¹¼ÙéãËè
ÃÐÂеèÍà¹×èͧ (continuation or maintenance
phase) ãªéÂÒ 2 ª¹Ô
´
¤×
Í
ÂÒäÍâ«ä¹ÍÐÊÔ
´
áÅÐäÃ
á¿Á»Ô
¹
à»ç¹àÇÅÒÍÂèÒ§¹éÍ 4 à´×͹ (18 ÊÑ»´ÒËì)
â´ÂÊÒÁÒöãËéÂÒä´éÑé§ÇѹÅÐ 1 ¤ÃÑé
§
ÊÑ»´ÒËìÅÐ 2 ¤ÃÑé
§
ËÃ×Í 3 ¤ÃÑ駵èÍÊÑ»´ÒË
ì
¹Í¡¨Ò¡¹ÕéºÒ§ÃÒÂÍÒ¨µéͧãËé¡ÒÃÃÑ¡ÉÒÃÇÁ 9
à´×͹
â´Âà¾ÔèÁÃÐÂеèÍà¹×èͧÍÕ¡ 3 à´×͹
´Ñ§µèÍ仹Õé
-â¾Ã§Çѳâä»Í´ (cavity) ÕèÂѧÁÕ¼Åà¾ÒÐ
àª×éͨҡàÊÁËÐà»ç¹ºÇ¡
ËÅѧÃÑ¡ÉÒ¹Ò¹ 2 à´×͹
-ÃÒÂÕèäÁèä´éÃѺ»ÃÐÒ¹ÂÒä¾ÃÒ«Ô¹ÒäÁ´
ìã¹
ÃÐÂÐà¢éÁ¢é
¹
-ÃÒÂÕèÃѺ»ÃÐÒ¹ÂÒäÍâ«ä¹ÍÐÊÔ´áÅÐäÃ
á¿Á»Ô
¹
ÊÑ»´ÒËìÅФÃÑé
§
áÅÐÂѧÁÕ¼ÅàÊÁËÐà»ç¹ºÇ¡
ÂÒ
¢¹Ò´µèÍÇÑ
¹
¢¹Ò´ 2 ¤ÃÑ駵èÍÊÑ»´ÒË
좹Ҵ 3 ¤ÃÑ駵èÍÊÑ»´ÒË
ì
Isoniazid 5 Á¡./¡¡. ÊÙ§ÊØ´ 300 Á¡. 15 Á¡./¡¡. ÊÙ§ÊØ´ 900 Á¡. 15 Á¡./¡¡. ÊÙ§ÊØ´ 900 Á¡.
Rifampin
Pyrazinamide
10 Á¡./¡¡. ÊÙ§ÊØ´ 600 Á¡.
15-30 Á¡./¡¡. ÊÙ§ÊØ´ 2 ¡.
10 Á¡./¡¡. ÊÙ§ÊØ´ 600 Á¡.
50-70 Á¡./¡¡. ÊÙ§ÊØ´ 4 ¡.
10 Á¡./¡¡. ÊÙ§ÊØ´ 600 Á¡.
50-70 Á¡./¡¡. ÊÙ§ÊØ´ 3 ¡.
Ethambutol 15-25 Á¡./¡¡. 50 Á¡./¡¡. 25-30 Á¡./¡¡.
Streptomycin 15 Á¡./¡¡. ÊÙ§ÊØ´ 1 ¡. 25-30 Á¡./¡¡. ÊÙ§ÊØ´ 1.5 ¡. 25-30 Á¡./¡¡. ÊÙ§ÊØ´ 1.5 ¡.
àÁ×èÍÊÔé¹ÊØ´¡ÒÃÃÑ¡ÉÒ
¡ÒÃÃѺ»ÃÐÒ¹ÂÒÃÑ¡ÉÒÇѳâä
¤ÇÃÃѺ»ÃÐÒ¹
àÇÅÒà´ÕÂÇ¡Ñ
¹
ÍÒ¨ãªéà»ç¹ÂÒª¹Ô´àÁç´ÃÇÁ
à¾×èͧèÒÂáÅÐ
ÊдǡÊÓËÃѺ¼Ùé»èÇÂ
Å´¤ÇÒÁ¼Ô´¾ÅҴ㹡ÒÃÃÑ
º
»ÃÐÒ¹
ÃÇÁÑé§Å´¡ÒÃà¡Ô´¡Òô×éÍÂÒã¹Í¹Ò¤µ
ÍÂèÒ§
äáç
´ÕÍÒ¨à¾ÔèÁÂÒª¹Ô´àÁç´á¡ºÒ§µÑ
Ç
ã¹ÃÒÂÕè¹éÓ˹Ñ
¡
µÑÇÁÒ¡¡ÇèÒ 90 ¡ÔâÅ¡ÃÑ
Á
à¾ÃÒТ¹Ò´ÂÒáµèÅеÑÇã¹ÂÒ
ª¹Ô´àÁç´ÃÇÁÍÒ¨äÁèà¾Õ§¾Í
àªè
¹
ÂÒä¾ÃÒ«Ô¹ÒäÁ´
ìà»ç
¹
µé
¹
ÃÐÂÐàÇÅÒÃÑ¡ÉÒÃÇÁ 6 à´×͹
â´ÂÁÕÂÒäÍâ«ä¹ÍÐ
ÊÔ´áÅÐäÃá¿Á»Ô
¹
µÅÍ´ÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒ
¶éÒµÔ
´
àª×éÍÇѳâäàÂ×èÍËØéÁÊÁͧ
¡Ãд١áÅТé
Í
ÍÒ¨ãËé¡ÒÃÃÑ¡ÉÒ
¹Ò¹¶Ö§ 12 à´×͹ (µÒÃÒ§Õè 6)
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
µÒÃÒ§Õè 6. áÊ´§ÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒÇѳâä¹Í¡»Í´
µÓá˹è
§
-µèÍÁ¹éÓàËÅ×ͧ
-¡Ãд١áÅТéÍ
-àÂ×èÍËØéÁ»Í´
-àÂ×èÍËØéÁËÑÇã¨*
-Ãкº»ÃÐÊÒÊèǹ¡ÅÒ§áÅÐàÂ×èÍËØéÁÊÁͧ*
-Çѳâä¡ÃШÒÂ
-ÃкºÒ§à´Ô¹»ÑÊÊÒÇÐ
-àÂ×èÍËØéÁªèͧéͧ
* á¹Ð¹ÓãËéãªéÂҤ͵Ôâ¤ÊàµÕÂÃÍ´ìÃèÇÁ´éÇÂ
¼Ùé»èÇÂÕèÁÕâäҧÍÒÂØáÃÃÁÍ×è
¹
¤ÇÃÃÐÇѧ㹡ÒÃ
ãªéÂÒÃÑ¡ÉÒÇѳâä
à¹×èͧ¨Ò¡ÂÒÁÕ»‾Ô¡ÃÔÂҡѺÂÒÍ×è¹æÁÒ¡
ÍÒ¨ÓãËéÃдѺÂÒ㹡ÃÐáÊàÅ×Í´à»ÅÕè¹á»Å§
¡ÒÃÃÑ¡ÉÒ
äÁèä´é¼ÅàèÒÕè¤ÇÃ
»ÃÐàÁÔ¹¡ÒõͺʹͧµèÍ¡ÒÃÃÑ¡ÉÒâ´ÂÊѧࡵ
¨Ò¡ÍÒ¡ÒÃáÅмšÒõÃǨàÊÁËÐ
¶éÒ¡è͹¡ÒÃÃÑ¡ÉÒÁÕ
¼ÅàÊÁËÐà»ç¹ºÇ¡
á¹Ð¹ÓãËéµÃǨàÊÁËÐËÅѧ¨Ò¡ÃÑ¡ÉÒ
¹Ò¹Êͧà´×͹
â´ÂäÁèµéͧµÃǨÀÒ¾ÃѧÊÕÇÔÂÒÕèÊͧ
à´×͹
ãËéµÃǨËÅѧàÊÃç¨ÊÔ鹡ÒÃÃÑ¡ÉÒÕèË¡à´×͹ä´éàÅÂ
áµèËÒ¡¡è͹¡ÒÃÃÑ¡ÉÒÁÕ¼ÅàÊÁËÐà»ç¹Åº
ãËéµÃǨÀÒ¾
ÃѧÊÕÇÔÂÒËÅѧÃÑ¡ÉÒÊͧà´×͹á¹
àÁ×èÍÃÑ¡ÉÒ¹Ò¹ 2 à´×͹áÅéÇÍÒ¡ÒÃäÁè´Õ¢Öé
¹
ÂѧÁÕ
¼Å¡ÒõÃǨàÊÁËÐà»ç¹ºÇ¡
ËÃ×ÍàÊÁËÐà»ÅÕ蹨ҡź
à»ç¹ºÇ¡
¶×ÍÇèÒ¡ÒÃÃÑ¡ÉÒÅéÁàËÅÇ
ËҡʧÊÑÂÇèÒ¡ÒÃÃÑ¡ÉÒ
ÅéÁàËÅǨҡ¡Òô×éÍÂÒ
ãËéà¾ÒÐàª×éÍÊÔè§Ê觵ÃǨÍÕ¡¤ÃÑé
§
ÃÇÁ¶Ö§¡ÒôÊͺ¤ÇÒÁäǵèÍÂÒ
á¹Ð¹ÓãËéà¾ÔèÁÂÒÍÕ
¡
ÍÂèÒ§¹éÍ 2 ª¹Ô
´
ÃÐËÇèÒ§ÃͼÅà¾ÒÐàª×éÍáÅФÇÒÁäÇ
µèÍÂÒ
à¾×èÍÅ´âÍ¡ÒÊ¡ÒôÓà¹Ô¹µèͧ͢¡Òô×éÍÂÒ
ÍÂèÒ§
äáç
´Õ¤ÇûÃÖ¡ÉÒ¼ÙéàªÕèÂǪÒ੾ÒÐÒ§´éÇÂ
ÃÐÂÐàÇÅÒ
6 à´×͹
6-9 à´×͹
6 à´×͹
6 à´×͹
9-12 à´×͹
6 à´×͹
6 à´×͹
6 à´×͹
â´Â»¡µÔäÁè¨Óà»ç¹µéͧµÃǨ¡ÒÃÓ§Ò¹¢Í§µÑ
º
áÅÐäµØ¡ÃÒÂ
¶éÒäÁèÁÕ¤ÇÒÁ¼Ô´»¡µÔµÑé§áµè¡è͹¡ÒÃÃÑ¡ÉÒ
ÃÒÂÕèÁÕ¤ÇÒÁ¼Ô´»¡µÔ¢Í§µÑºËÃ×Íäµ
ËÃ×ÍÁÕÍÒ¡ÒÃÕè
ºè§ºÍ¡¤ÇÒÁ¼Ô´»¡µÔ¤ÇõÃǨµÔ´µÒÁ¡ÒÃÓ§Ò¹ÍÂèÒ§
µèÍà¹×èͧ
ÃÇÁ¶Ö§µÃǨÇÑ´ÃдѺÊÒµÒáÅСÒÃÁͧàËç
¹
ÊÕã¹ÃÒÂÕèä´éÃѺÂÒÍÕáÁºÙÍÅ
ÁÒ¡¡ÇèÒ 10-15
ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ËÃ×ÍÃѺ»ÃÐÒ¹
ÂÒÁÒ¹Ò¹¡ÇèÒ 2 à´×͹
¡ÒÃãªéÂÒª¹Ô´àÁç´ÃÇÁ42
à¹×èͧ¨Ò¡¡ÒÃÃÑ¡ÉÒÇѳâäµéͧãªéÂÒËÅÒª¹Ô
´
ÃèÇÁ¡Ñ
¹
ÃÇÁÑ駻ÃѺ¢¹Ò´ÂÒµÒÁ¹éÓ˹ѡµÑǢͧ¼Ùé»èÇÂ
ÓãËéµéͧÃѺ»ÃÐÒ¹ÂÒ¶Ö§ 9-12 àÁç´µèÍÇÑ
¹
ã¹ÃÐÂÐ
2 à´×͹áá
áÅÐ 3-9 àÁç´µèÍÇÑ
¹
ã¹ÃÐÂÐ 4-6 à´×͹
¶Ñ´ÁÒ
¨Ö§ÁÕ¡ÒùÓÂÒª¹Ô´àÁç´ÃÇÁÁÒãªéà¾×èÍãËé¨Ó¹Ç¹
àÁç´ÂÒÅ´àËÅ×Íà¾Õ§ 3-5 àÁç´µèÍÇÑ
¹
«Ö觧èÒµèÍ¡ÒÃÃÑ
º
»ÃÐÒ¹ÂÒ
»éͧ¡Ñ¹¡ÒÃÃѺ»ÃÐÒ¹ÂÒäÁè¤Ãº
Ñ駹ÕéÂÑ
§
§èÒµèÍ¡Òäӹdz¢¹Ò´ÂÒáÅСÒÃÊÑè§ÂҢͧá¾Â
ì
ÃÒ§ҹ¨Ò¡»ÃÐàÈÎèͧ¡§
ã¹»Õ¾.È. 2532 ¾ºÇè
Ò
à¾Õ§
ÃéÍÂÅÐ 1 ¢Í§¼Ùé»èÇÂÕèÃѺ»ÃÐÒ¹ÂÒª¹Ô´àÁç´ÃÇÁÑé
§
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
ËÁ´ 312 ÃÒÂÕèáÊ´§¤ÇÒÁàËç¹à¡ÕèÂǡѺ¤ÇÒÁÅÓºÒ¡ã¹
¡ÒÃÃѺ»ÃÐÒ¹ÂÒ
à»ÃÕºàÕº¡ÑºÃéÍÂÅÐ 5 ¢Í§¼Ùé»èÇÂ
308 ÃÒÂ
ÕèÃѺ»ÃÐÒ¹ÂÒª¹Ô´á¡àÁç
´
Êèǹ¼Å¢éÒ§à¤Õ§
¨Ò¡ÂÒ
¾ºÇèÒàèҡѹÑé§Êͧ¡ÅØè
Á
Êèǹ»ÃÐàȺÃÒ«Ô
Å
áÅÐáÍ¿ÃÔ¡Òãµé¡ç¾º»ÑËÒ¡Òô×éÍÂÒŴŧ (ÃéÍÂÅÐ
5.4 ŴŧàËÅ×ÍÃéÍÂÅÐ 0.9 áÅÐÃéÍÂÅÐ 4 ŴŧàËÅ×
Í
ÃéÍÂÅÐ 1.1 µÒÁÅӴѺ) ËÅѧ¨Ò¡ãªéÂÒª¹Ô´àÁç´ÃÇÁã¹
»Õ¾.È. 2537-2540
»Ñ¨¨ØºÑ¹»ÃÐàÈÊËÃÑ°ÍàÁÃÔ¡Ò
ÁÕ¡ÒÃãªéÂÒäÃ
¿ÒàÁ (rifamate) «Öè§à»ç¹Êèǹ¼ÊÁ¢Í§ÂÒäÍâ«ä¹
ÍÐÊÔ´ 150 ÁÔÅÅÔ¡ÃÑ
Á
áÅÐäÃá¿Á¾Ô«Ô¹ 300 ÁÔÅÅÔ¡ÃÑ
Á
ÍÕ¡ª¹Ô´Ë¹Ö觤×
Í
äÿÒàµÍÃì (rifater) «Ö觼ÊÁÂÒäÍâ«
ä¹ÍÐÊÔ´ 50 ÁÔÅÅÔ¡ÃÑ
Á
ÂÒäÃá¿Á¾Ô«Ô¹ 120 ÁÔÅÅÔ¡ÃÑ
Á
áÅÐÂÒä¾ÃÒ«Ô¹ÒäÁ´ì 300 ÁÔÅÅÔ¡ÃÑ
Á
ºÒ§»ÃÐàÈÍÒ¨
ÁÕ¡ÒüÊÁÂÒËÅÑ¡Ñé§ 4 ª¹Ô
´
ã¹àÁç´à´ÕÂÇ
ÂÒª¹Ô´àÁç
´
ÃÇÁàËÁÒÐÊÓËÃѺÊÙµÃÇѹÅФÃÑé
§
ºÒ§áËè§ÍÒ¨ÁÕ¡ÒÃãªé
ÂÒäÿÒàÁ¤Ùè¡ÑºÂÒäÍâ«ä¹ÍÐÊÔ´ÊÑ»´ÒËìÅÐ 2 ¤ÃÑé
§
ÍÂèÒ§
äáç
´ÕáÁéäÁèÁÕËÅÑ¡°Ò¹Â×¹Âѹá¹èªÑ´ÇèÒÂÒª¹Ô´àÁç´ÃÇÁ
ÁÕ»ÃÐÊÔ¸ÔÀÒ¾à˹×Í¡ÇèÒÂÒª¹Ô´á¡
áµè¼ÙéàªÕèÂǪÒ
ËÅÒÂèÒ¹á¹Ð¹ÓãËéãªéÂÒª¹Ô´àÁç´ÃÇÁ
ã¹ÃÒÂÕèäÁè
ÊÒÁÒöÃѺ»ÃÐÒ¹ÂÒª¹Ô´á¡àÁç´Ø¡ÇѹẺÇÔ
¸Õ
DOTs ä´é
´Ñ§¹Ñé
¹
ͧ¤ì¡ÒÃ͹ÒÁÑÂâÅ¡ (WHO) áÅÐ
International Union Against Tuberculosis and
Lung Disease (IUATLD) ŧ¤ÇÒÁàËç¹ÇèÒ¡ÒÃãªéÂÒ
ª¹Ô´àÁç´ÃÇÁÁÕ¢éÍ´Õ¤×
Í
ºÃÔËÒÃÂÒ§èÒÂ
Å´¤ÇÒÁ¼Ô´¾ÅÒ´
¨Ò¡¡ÒÃÃѺ»ÃÐÒ¹ÂÒ
ÓãËéÅ´âÍ¡ÒÊà¡Ô´¡Òô×éÍÂÒä´é
ã¹Í¹Ò¤µ
¨Ö§ÁÕÊÙµÃÂÒª¹Ô´àÁç´ÃÇÁµÒÁµÒÃÒ§Õè 7 à»ç
¹
µé
¹
¶Ö§¡ÃйÑ鹡çµÒÁáÁéÇèÒãªéÂÒª¹Ô´àÁç´ÃÇÁáÅé
Ç
áµè
ͧ¤ì¡ÒÃ͹ÒÁÑÂâÅ¡Âѧá¹Ð¹ÓãËéãªéÇÔ¸Õ DOTs ¤Çº¤Ùèä»
´éÇÂ
µÒÃÒ§Õè 7. áÊ´§ÊÙµÃÂÒª¹Ô´àÁç´ÃÇÁª¹Ô´µèÒ§æÕèä´éÃѺ¡ÒÃá¹Ð¹Ó¨Ò¡ WHO
R : rifampicin, H : isoniazid, Z : pyrazinamide, E : ethambutol
ª¹Ô´ÂÒÃÇÁ
¢¹Ò´ÂÒ
Rifampicin + isoniazid +
pyrazinamide + ethambutol
R 150 mg + H 75 mg + Z 400 mg + E 275 mg
Rifampicin + isoniazid + pyrazinamide R 150 mg + H 75 mg + Z 400 mg
R 60 mg + H 30 mg + Z 150 mg (paediatric)
R 60 mg + H 30 mg (paediatric)
Isoniazid + ethambutol H 150 mg + E 400 mg
Thioacetazone + isoniazid T 50 mg + H 100 mg
T 150 mg + H 300 mg
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
¢éͤÇÃÃÐÇѧ¢Í§¡ÒÃãªéÂÒª¹Ô´àÁç´ÃÇÁ¤×
Í
äÁè
ä´éÃдѺÕèãªéä´é (bioavailability) ¢Í§ÂÒäÃá¿Á¾Ô
«Ô
¹
â´ÂÍÒ¨à¡Ô´¨Ò¡¡ÒüÅÔµÂÒÕèäÁèä´éÁҵðҹ
ËÃ×
Í
¡Òôٴ«ÖÁÂÒäÁè´Õã¹¼Ùé»èÇÂÕèÁÕâäҧÍÒÂØáÃÃÁÃèÇÁ
àªè
¹
âäàÍ´Ê
ìÓãËé¡ÒÃãªéÂÒäÁèä´éÁҵðҹ
¡èÍãËéà¡Ô´¡ÒÃ
ÃÑ¡ÉÒÅéÁàËÅÇáÅд×éÍÂÒµÒÁÁÒ
¡Òô×éÍÂÒ
»ÑËÒàª×éÍÇѳâä´×éÍÂÒÁÒ¡¡ÇèÒ˹Ö觪¹Ô´¹Ñé
¹
ÂÒ¡
µèÍ¡ÒÃÃÑ¡ÉÒ
¨Ò¡¡ÒÃÊÓÃǨ¢Í§ Dye áÅФ³Ð46 ã¹¼Ùé
»èÇÂÇѳâäÃÒÂãËÁèÃÇÁ 136 »ÃÐàÈ
ÁÕ¡Òô×éÍÂÒËÅÒÂ
¢¹Ò¹
¶Ö§ÃéÍÂÅÐ 3.2 ¡ÒÃà¡Ô´¡ÒþѲ¹Ò¢Í§àª×éÍà»ç
¹
ÊÒ¾ѹ¸ìØÕè´×éÍÂÒ
â´Â¡ÒÃÕèàª×éÍÇѳâä¾Ñ²¹ÒÊÒ¾ѹ¸
ìØ
´×é͵èÍÂÒà¾Õ§˹Ö觪¹Ô
´
äÁèÓãËéà¡Ô´¡Òô×éÍÂÒÕèÊÓ¤Ñ
Ò§¤ÅÔ¹Ô
¤
àª×éÍÇѳâäÁÑ¡´×é͵èÍÂÒäÍâ«ä¹ÍÐÊÔ
´
(isoniazid) ÁÒ¡ÕèÊØ
´
¡èÍãËéà¡Ô´¡Òô×é͵èÍÂÒäÃá¿Á¾Ô
«Ô¹ (rifampicin) µÒÁÁÒ
àÁ×èÍàª×éÍ´×é͵èÍÂÒËÅÒª¹Ô
´
ÁÒ¡¢Öé
¹
¨Ö§ÓãËé¡ÒÃÃÑ¡ÉÒäÁèä´é¼ÅàèÒÕè¤ÇÃ
ÍÂèÒ§äÃ
¡ç
´ÕÊèǹãËèÁÑ¡à¡Ô´¡Òô×éÍÂÒÀÒÂËÅÑ
§
àªè
¹
ÁÕàª×éÍ»ÃÔÁÒ³
ÁÒ¡ã¹â¾Ã§¢Í§»Í´
¡ÒÃÃѺ»ÃÐÒ¹ÂÒäÁèÊÁèÓàÊÁÍ
äÁè
¶Ù¡µéͧµÒÁÊÙµÃËÃ×Í¢¹Ò´ÂÒ
¹Í¡¨Ò¡¹Õé¤ÇÃʧÊÑ
Â
ã¹
¡Ã³ÕÕèÁÕ»ÃÐÇѵÔà¤ÂÃÑ¡ÉÒÇѳâäÁÒ¡è͹
ÊÑÁ¼ÑÊã¡ÅéªÔ
´
¼Ùé»èÇÂÃÒÂÍ×è¹ÕèÁÕËÅÑ¡°Ò¹ÇèÒ´×éÍÂÒ
ËÃ×ÍÍÂÙèã¹¾×é¹ÕèÕè
ÁÕ
ÍغѵԡÒóì¡Òô×éÍÂÒÊÙ
§
«Öè§ÓãËé¡ÒÃÃÑ¡ÉÒÅéÁàËÅÇ
¨Ö
§
ÁÕ¡ÒÃá¹Ð¹ÓÇÔ¸Õ¡ÒôÙáżÙé»èÇÂÇѳâä´×éÍÂÒ (µÒÃÒ§Õè 7)
áÅСÒùÓÂÒª¹Ô´µèÒ§æÁÒãªé¹Í¡à˹×ͨҡÊÙµÃÂÒËÅÑ
¡
(µÒÃÒ§Õè 8) ÍÂèÒ§äáç
´ÕÂÒàËÅèÒ¹ÕéÁռŢéÒ§à¤Õ§ÁÒ¡¡Çè
Ò
ÃÒ¤Òᾧ¡Çè
Ò
ÃÇÁÑ駻ÃÐÊÔ¸ÔÀÒ¾´éÍ¡ÇèÒÊÙµÃÂÒËÅÑ
¡
¡ÒÃãªéÂÒËÃ×ÍàÅ×Í¡ÊÙµÃÂÒ¤ÇÃä´éÃѺ¤Óá¹Ð¹Ó¨Ò¡¼ÙéàªÕèÂÇ
ªÒ੾ÒÐ
ÃÇÁ¶Ö§¡ÒÃÃѺ»ÃÐÒ¹ÂÒâ´ÂÁÕ¼ÙéÊѧࡵ¡Òó
ì
àÃÕ¡ÇÔ¸Õ directly observed therapys (DOTs)
ÃÒ§ҹ¨Ò¡ Weis ¾ºÇèÒÍѵÃÒ¡Òô×éÍÂÒáÅСÒáÅÑ
º
à»ç¹«éÓŴŧ㹡ÅØèÁÕèãªéÇÔ¸Õ DOTs
ÀÒ¾áÊ´§¤ÇÒÁªØ¡¢Í§¡Òô×éÍÂÒÃÑ¡ÉÒÇѳâä㹼Ùé»èÇÂÃÒÂãËÁè
»Õ¾.È. 2537-2543 ÃÒ§ҹ¨Ò¡ WHO48
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
µÒÃÒ§Õè 7. ¤Óá¹Ð¹Ó㹡ÒôÙáżÙé»èÇÂÇѳâä´×éÍÂÒ
DOTs : directly observed therapy
-äÁèà¾ÔèÁÂÒà¾Õ§µÑÇà´ÕÂÇ㹡ÒÃÃÑ¡ÉÒÇѳâä´×éÍÂÒ
-àÁ×èÍàÃÔèÁ¡ÒÃÃÑ¡ÉÒãËÁè¤ÇùÓÂÒÕèäÁèà¤ÂãªéÍÂèÒ§¹éÍ 3 ª¹Ô
´
ÁÒ´Êͺ¤ÇÒÁäǢͧàª×é
Í
â´Â 1 ª¹Ô
´
¤ÇÃà»ç¹ª¹Ô´©Õ
´
-ÍÒ¨ãªéÂÒä´é¶Ö§ 4-6 ª¹Ô´ã¹ÃÒÂÕè´×éÍÂÒËÅÒ¢¹Ò¹
-¤ÇÃãªéÇÔ¸Õ DOT ã¹¼Ùé»èÇÂØ¡ÃÒÂ
-äÁè¤ÇÃÃѺ»ÃÐÒ¹ÂÒẺàÇé¹ÇÑ
¹
¤ÇÃãªéÊÙµÃÂÒẺÃѺ»ÃÐҹءÇÑ
¹
¡àÇ鹪¹Ô´©Õ
´
-äÁè¤ÇÃãªéÂÒÕè¼Å¡ÒôÊͺҧËéͧ»‾ԺѵԡÒÃÃÒ§ҹÇèÒ´×éÍÂÒ
-¡Òô×éÍÂÒäÃá¿Á»Ô¹ÁÑ¡´×éÍÂÒäÿҺٵԹáÅÐäÿÒà¾ç¹µÔ¹´éÇÂ
-äÁ辺¡Òô×éÍ¢éÒÁ¡Ñ¹ÃÐËÇèÒ§ÂÒÊàµÃçºâµäÁ«Ô¹áÅÐÂÒ©Õ´Í×è¹æ
-äÁè¹ÔÂÁãªéÂÒ©Õ´ 2 ª¹Ô´¾ÃéÍÁ¡Ñ
¹
à¹×èͧ¨Ò¡ÂѧäÁèä´éÃѺ¡ÒÃÂ×¹Âѹ»ÃÐÊÔ¸ÔÀÒ¾áÅмŢéÒ§à¤Õ§
-ËÒ¡¾º¡Òô×éÍÂÒÊàµÃçºâµäÁ«Ô¹ª¹Ô´à´ÕÂÇ
ãËéÃÐÇѧàª×é
Í
M. bovis ÁÒ¡¡Çè
Ò
M. tuberculosis
µÒÃÒ§Õè 8 ÊÙµÃÂÒÃÑ¡ÉÒÇѳâä»Í´´×éÍÂÒ
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
àÍ¡ÊÒÃÍéÒ§ÍÔ
§
1.
Harrison's Principles of Internal Medicine
16th Edition. Tuberculosis chap 150, pp
2.
World Health Organization Fact sheet no
104, revised March 2004. Geneva
(Switzerland)7 World Health Organization;
2004.
3.
Gardner CA, Acharya T, Pablos-Mendez
A. The global alliance for tuberculosis
drug development accomplishments and
future directions. Clin Chest Med. 2005
26:341-7.
4.
ÊÁÒ¤Á»ÃÒºÇѳâäáË觻ÃÐàÈäÂã¹¾ÃкÃÁÃÒ
ªÙ»¶ÑÁÀì, ¡ÃÁ¤Çº¤ØÁâäµÔ´µè
Í
¡ÃÐÃǧ
ÊÒ¸ÒóÊØ
¢
ÊÁÒ¤ÁÍØÃàǪªìáË觻ÃÐàÈäÂ.
á¹ÇÒ§¡ÒÃÇÔ¹Ô¨©ÑÂáÅÐÃÑ¡ÉÒÇѳâä㹻ÃÐàÈä
Â
¾ÔÁ¾ì¤ÃÑé§Õè 2 (©ºÑº»ÃѺ»Ãا)
5.
ÈÙ¹Âì¢éÍÁÙÅâäµÔ´àª×éÍáÅоÒËйÓâä
6.
Jawahar, Current trends in chemotherapy
of tuberculosis. Indian J Med Res, Oct
2004,pp398-417.
7.
Rich A, Follis RH. 1938. The inhibitory
effect of sulfanilamide on the development
of experimental tuberculosis of the guinea
pig. Bull. Johns Hopkins Hosp.62:77-84.
8.
Waksman SA. Suppressive effect of
streptomycin on the growth of tubercle
bacilli in laboratory animals. Am J Public
Health 1944;34:358.
9.
Benator D, Bhattacharya M, Bozeman L,
Burman W, Cantazaro A, Chaisson R,
et al. Tuberculosis Trials Consortium.
Rifapentine and isoniazid once a week
versus rifampicin and isoniazid twice a
week for treatment of drug-susceptible
pulmonary tuberculosis in HIV-negative
patients: a randomised clinical trial. Lancet.
2002;360:528-34.
10.
Lehmann J. 1946. p-aminosalicylic acid
in the treatment of tuberculosis. Lancet
1:15-16.
11.
TEMPEL CW, HUGHES FJ Jr, MARDIS
RE, TOWBIN MN, DYE WE. Combined
intermittent regimens employing
streptomycin and para-aminosalicylic acid
in the treatment of pulmonary tuberculosis;
a comparison with daily and intermittent
dosage schedules. Am Rev Tuberc.
1951;63:295-311.
12.
Mitchison DA. Role of individual drugs
in the chemotherapy of tuberculosis. Int
J Tuberc Lung Dis. 2000;4:796-806.
13.
East African/British Medical Research
Councils Study. Results at 5 years of a
controlled comparison of a 6-month and
a standard 18-month regimen of
chemotherapy for pulmonary tuberculosis.
Am Rev Respir Dis 1977;116:3-8.
14.
East African/ British Medical Research
Councils. Controlled clinical trial of shortcourse (6-month) regimens of chemotherapy
for treatment of pulmonary
tuberculosis. Lancet 1972;1:1079-85.
15.
American Thoracic Society, Centers for
Disease Control and Prevention, and
Infectious Diseases Society of America.
Treatment of tuberculosis. MMWR
Recomm Rep 2003;52:1-77.
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
16.
American Thoracic Society, CDC and
Prevention, and Infectious Diseases Society
of America. Update recommendation for
treatment of tuberculosis. Am family phy.
Nov 2003.
17.
Sahbazian B, Weis SE. Treatment of active
tuberculosis: challenges and prospects. Clin
Chest Med. 2005;26:273-82.
18.
American Thoracic Society, Centers for
Disease Control and Prevention. Treatment
of tuberculosis and tuberculosis infection
in adults and children. Am J Respir Crit
Care Med 1994;149:1359-74.
19.
Up to date version 13.2.
20.
Somoskovi et al. Review The molecular
basis of resistance to isoniazid, rifampin,
and pyrazinamide in Mycobacterium
tuberculosis Respiratory Research 2001
Vol 2 No 3.
21.
Black M, Mitchell JR, Zimmerman HJ,
Ishak KG, Epler GR. Isoniazid-associated
hepatitis in 114 patients. Gastroenterology.
1975;69:289-302.
22.
Garibaldi RA, Drusin RE, Ferebee SH,
Gregg MB. Isoniazid-associated
hepatitis. Report of an outbreak. Am
Rev Respir Dis. 1972;106:357-65.
23.
American Thoracic Society. Report on
the Ad Hoc Committee on isoniazid and
liver disease. Centers for Disease Control,
Department of Health, Education and
Welfare. March 17-18, 1971. Isoniazid and
liver disease. Am Rev Respir Dis 1971;
104:454.
24.
Steele MA, Burk RF, DesPrez RM. Toxic
hepatitis with isoniazid and rifampin. A
meta-analysis. Chest. 1991;99:465-71.
25.
Nolan CM, Goldberg SV, Buskin SE.
Hepatotoxicity associated with isoniazid
preventive therapy: a 7-year survey
from a public health tuberculosis clinic.
JAMA. 1999;281:1014-8.
26.
Grosset J, Leventis S. Adverse affects of
rifampin. Rev Infect Dis 1983;5:S440-50.
27.
Shoen CM, DeStefano MS, Cynamon MH.
2000. Durable cure for tuberculosis: rifalazil
in combination with isoniazid in a murine
model of Mycobacterium tuberculosis
infection. Clin. Infect. Dis. 30(Suppl.
3):S288-90.
28.
Yee, Valiquette, Pelletier, et al.: Side
Effects of TB Therapy. Am J Respir Crit
Care Med Vol 167. pp 1472-1477, 2003.
29.
Pilheu JA, Maglio F, Cetrangolo R, Pleus
AD. Concentrations of ethambutol in the
cerebrospinal fluid after oral administration.
Tubercle. 1971;52:117-22.
30.
Leibold JE. The ocular toxicity of
ethambutol and its relation to dose.
Ann N Y Acad Sci. 1966;135:904-9.
31.
Murray FJ. A pilot study of cycloserine
toxicity: a United States Public Health
Service cooperative clinical investigation.
Am Rev Respir Dis 1956;74:196-209.
32.
Joint Committee on the Study of
Streptomycin. The effects of streptomycin
on tuberculosis in man. JAMA 1947;135:
634-41.
»ÕÕè 19 ©ºÑºÕè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
33.
Black RE, Lau WK, Weinstein RJ, Young
LS, Hewitt WL. Ototoxicity of amikacin.
Antimicrob Agents Chemother. 1976;9:95661.
34.
Rossouw JE, Saunders SJ. Hepatic
complications of antituberculous therapy.
Q J Med 1975;XLIV:1-16.
35.
Nuermberger EL, Yoshimatsu T, Tyagi
S, O Brien RJ, Vernon AN, Chaisson RE,
Bishai WR, Grosset JH. Moxifloxacincontaining
regimen greatly reduces time
to culture conversion in murine
tuberculosis. Am J Respir Crit Care Med.
2004;169:421-6.
36.
David HL. Probability distribution of
drug-resistant mutants in unselected
populations of Mycobacterium
tuberculosis. Appl Microbiol.
1970;20:810-4.
37.
Centers for Disease Control and Prevention.
Prevention and treatment of tuberculosis
among patients infected with human
immunodeficiency virus: principles of
therapy and revised recommendations.
MMWRMorb Mortal Wkly Rep 1998;47
:1-51.
38.
Horsburgh CR Jr, Feldman S, Ridzon R;
Infectious Diseases Society of America.
Practice guidelines for the treatment of
tuberculosis. Clin Infect Dis. 2000;31:6339.
39.
Essential components of a tuberculosis
control program: recommendations of the
Advisory Council for the Elimination of
Tuberculosis. MMWR Morb Mortal Wkly
Rep 1995;44:1-16.
40.
Treatment of tuberculosis: Guidelines of
national programs. 3rd ed. Geneva: WHO;
2003.
41.
Mitchison DA, Nunn AJ. Influence of
initial drug resistance on the response to
short-course chemotherapy of pulmonary
tuberculosis. Am Rev Respir Dis.
1986;133:423-30.
42.
Bjorn Blomberg, Sergio Spinaci,Bernard
Fourie,Richard Laing. The rationale for
recommending fixed-dose combination
tablets for treatment of tuberculosis.
Bulletin of the World Health Organization,
2001,79:61-8.
43.
Hong Kong Chest Service/British Medical
Research Council. Acceptability,
compliance, and adverse reactions when
isoniazid, rifampin, and pyrazinamide are
given as a combined formulation or
separately during three-times-weekly
antituberculosis chemotherapy. American
Review of Respiratory Disease, 1989,140:
1618-22.
44.
Pablos-Mendez Aet al. Global surveillance
for antituberculosis drug resistance, 19941997.
World Health Organization
International Union against Tuberculosis
and Lung Disease Working Group on
Anti-Tuberculosis Drug Resistance
Surveillance. N Engl J Med, 1998;338:
1641-9.
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
45.
The use of essential drugs: ninth report of
the WHO Expert Committee (including
the revised Model List of Essential Drugs).
Geneva, World Health Organization, 2000
(WHO Technical Report Series, No. 895)
46.
Dye C, Espinal MA, Watt CJ, Mbiaga
C, Williams BG. Worldwide incidence of
multidrug-resistant tuberculosis. J Infect
Dis 2002;185:1197-202.
47.
Weis SE, Slocum PC, Blais FX, et al.
The effect of directly observed therapy
on the rates of drug resistance and relapse
in tuberculosis N Engl J Med 1994;330:117984.
48.
Iruka N Okeke,et al. Antimicrobial
resistance in developing countries. Part I:
recent trends and current status. Lancet
Infect Dis 2005;5:481-93.
Sponsor Documents